US20200140842A1 - Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing - Google Patents

Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing Download PDF

Info

Publication number
US20200140842A1
US20200140842A1 US16/616,014 US201816616014A US2020140842A1 US 20200140842 A1 US20200140842 A1 US 20200140842A1 US 201816616014 A US201816616014 A US 201816616014A US 2020140842 A1 US2020140842 A1 US 2020140842A1
Authority
US
United States
Prior art keywords
fusion protein
nucleic acid
cas9
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/616,014
Inventor
J. Keith Joung
James Angstman
Jason Michael GEHRKE
Julian Grunewald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to US16/616,014 priority Critical patent/US20200140842A1/en
Publication of US20200140842A1 publication Critical patent/US20200140842A1/en
Assigned to THE GENERAL HOSPITAL CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GEHRKE, Jason Michael, GRUNEWALD, Julian, ANGSTMAN, James, JOUNG, J. KEITH
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Definitions

  • Described herein are methods and compositions for improving the genome-wide specificities of targeted base editing technologies.
  • Base editing (BE) technology is based on the fusion of a DNA binding domain as e.g. catalytically inactive or nicking Cas9 (dCas9 or nCas9) to a cytidine or adenine deaminase and a uracil glycosylase inhibitor (UGI).
  • dCas9 or nCas9 catalytically inactive or nicking Cas9
  • a cytidine or adenine deaminase a uracil glycosylase inhibitor
  • UFI uracil glycosylase inhibitor
  • CRISPR base editor platforms possess the unique capability to generate precise, user-defined genome-editing events without the need for a donor DNA molecule.
  • Base editors that include a single strand nicking CRISPR-Cas9 (nCas9) protein fused to a cytidine deaminase domain and uracil glycosylase inhibitor (UGI) (BE3) efficiently induce cytosine-to-thymine (C-to-T) base transitions in a site-specific manner as determined by the CRISPR guide RNA (gRNA) spacer sequence 1 .
  • BEs bipartite BEs
  • ZFs engineered zinc-fingers
  • ZF-deaminase deaminase enzymes
  • nCas9-UGI binding site thereby reconstituting the full functionality of a BE around adjacently-targeting DNA sequences and stimulating robust DNA modification.
  • efficient activity of this bipartite enzyme relies on the specific adjacent binding of two separate DNA-binding domains, it should increase the specificity of base editing by decreasing the ability of its constituent pieces to function robustly at any of their off-target binding sites in genomic DNA, so long as adjacent binding of the two constituents does not occur at that site.
  • Spatially separating nCas9 from the deaminase domain should also reduce the synergistically induced indel formation adjacent to and at the site of targeted base editing, thereby enhancing overall product purity and off-target indel formation.
  • Cas9 orthologs and variants may be deficient for CRISPR-mediated DNA-binding and genome- or base editing (such as PAM-interacting deficient (PID) mutants or type-II-C Cas9s 14-16 ), we noted that rescuing their DNA-targeting capabilities by fusing them to an adjacently-targeted engineered DNA binding domain such as a ZF or a TALE may allow them to constitute the basis of BEs with better specificity profiles than those described as yet in the literature.
  • PAM-interacting deficient (PID) mutants or type-II-C Cas9s 14-16 PAM-interacting deficient
  • the resulting protein specifies a total DNA target sequence comprising both target sites, increasing the number of total bases specified by the complex and thereby imparting greater overall specificity to the technique.
  • Use of these proteins as the basis of base editors would therefore constitute a more specific base editing platform.
  • fusion proteins useful in a bipartite cytosine base editor system comprising: (i) a first fusion protein comprising a non-R-loop-forming programmable DNA binding domain, preferably a transcription-activator-like effector (TALE) or zinc finger array (ZF), fused to a deaminase enzyme, or an active portion thereof, optionally with a linker therebetween, or (ii) a second fusion protein comprising an R-loop-forming Cas9 protein that lacks nuclease activity or is a nickase, but can interact with a guide RNA and target DNA, fused to a Uracil glycosylase inhibitor (UGI), optionally with a linker therebetween.
  • TALE transcription-activator-like effector
  • ZF zinc finger array
  • the first fusion protein comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
  • AICDA activation induced cytidine deaminase
  • CDA1 cytosine deaminase 1
  • CDA2 cytosine deaminase acting on tRNA
  • the second fusion protein comprises an SpCas9 nickase or inactive nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or an inactive Cpf1 (dCpf1) protein.
  • the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
  • the DNA binding domain comprises a zinc finger DNA binding array.
  • monomeric fusion proteins comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, and optionally (iv) a fourth portion comprising a Uracil DNA glycosylase inhibitor (UGI), optionally with peptide linkers in between some or all of the first, second, third, or fourth portions, and wherein the domains (i)-(iv) can be in any order.
  • a first portion comprising a deaminase enzyme, or an active portion thereof
  • a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase
  • fusion proteins comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, such as type-II-C Cas9 orthologs or similarly deficient species, and (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, optionally with peptide linkers in between some or all of the first, second, or third portions, and wherein the domains (i)-(iii) can be in any order.
  • These fusion proteins can be used in combination with a protein comprising a Uracil DNA glycosylase inhibitor (UGI), e.g., in the methods described herein.
  • Uracil DNA glycosylase inhibitor Uracil DNA glycosylase inhibitor
  • the first portion comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
  • AICDA activation induced cytidine deaminase
  • CDA1 cytosine deaminase 1
  • CDA2 cytosine deaminase acting on tRNA
  • the second portion comprises an SpCas9 nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or a type-II-C Cas9 ortholog.
  • the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
  • the second portion comprises PlCas9, ClCas9, or NcCas9; or SpCas9, SaCas9, or CjCas9 with a mutations to a PAM interacting domain (PID), e.g., as shown in Table 2.
  • PAM interacting domain PAM interacting domain
  • the DNA binding domain comprises a zinc finger DNA binding array.
  • compositions comprising a purified fusion protein described herein, optionally further comprising a guide RNA that interacts with the Cas9 portion of the fusion protein.
  • the composition includes one or more ribonucleoprotein (RNP) complexes.
  • nucleic acids encoding the fusion proteins described herein, vectors comprising the nucleic acids, and isolated host cells comprising and/or expressing the fusion proteins.
  • compositions comprising a nucleic acid encoding the fusion proteins described herein.
  • the methods include contacting the nucleic acid with fusion proteins described herein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to (e.g., within 1, 2, 5, 10, 15, or 20 nts of) the selected cytosines.
  • gRNA guide RNA
  • the nucleic acid is in a cell, preferably a eukaryotic cell.
  • the methods include expressing in the cell, or contacting the cell with, the fusion proteins described herein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to (e.g., within 1, 2, 5, 10, 15, or 20 nts of) the selected cytosine.
  • gRNA guide RNA
  • the fusion protein is delivered as an RNP, or as an mRNA or plasmid comprising a sequence encoding the fusion protein.
  • RNP ribonucleoprotein
  • the fusion protein is delivered as an RNP, or as an mRNA or plasmid comprising a sequence encoding a fusion protein described herein.
  • Also provided herein are methods for deaminating a selected cytosine in a nucleic acid the method comprising contacting the nucleic acid with a fusion protein or base editing system described herein.
  • compositions comprising a purified a fusion protein or base editing system as described herein.
  • nucleic acids encoding a fusion protein or base editing system described herein, as well as vectors comprising the nucleic acids, and host cells comprising the nucleic acids, e.g., stem cells, e.g., hematopoietic stem cells.
  • FIG. 1 Cas9 PID mutants or Type II-C Cas9s as chimeric BE technologies with ZFs.
  • the 6-finger zinc finger array and UGI are fused to the C-terminus of nCas9 and any of the wild type or engineered deaminase domains is fused to the N-terminus of the nCas9.
  • the ZF binding sequence is directly adjacent to the gRNA target site. In this model, binding of the ZF is a prerequisite for formation of the R-loop by nCas9, greatly reducing the number of possible off-target sites at which R-loops might be formed to those that are adjacent to a ZF binding site.
  • TALEs instead of ZFs is also described herein.
  • FIG. 2 Type II-C Cas9s demonstrate increased binding and nuclease activity at their target sites in human cells when fused to 3-finger ZFs.
  • a chromosomally-integrated EGFP gene is used as a reporter for binding (via steric hindrance of transcription) or nuclease activity (via NHEJ-mediated small insertion and deletions in the coding sequence).
  • Transient transfection of plasmids expressing various Cas9 orthologs and gRNAs with 20- or 23-nucleotide homology to the EGFP reporter results in disruption or repression of EGFP, resulting in EGFP-negative cells when assayed by flow cytometry.
  • addition of a ZF fusion partner increases the EGFP disruption rate of the Cas9 ortholog tested.
  • addition of a ZF fusion partner to PlCas9 increases EGFP disruption activity of this ortholog from background levels to 85%.
  • FIG. 3 Diagram of a bipartite base editing architecture.
  • a nicking Cas9 (nCas9) is targeted to the deamination site by a guide RNA (gRNA).
  • gRNA guide RNA
  • the zinc finger-deaminase complex targets dsDNA near the formed R-loop.
  • Target cytosines in the editing window get deaminated.
  • Nicking Cas9 induces a single strand break (SSB) in the genomic DNA (non-deaminated strand) thus attracting DNA repair proteins, e.g. involving the mismatch repair (MMR) pathway.
  • MMR mismatch repair
  • FIG. 4 Superimposed cytosine to thymine (C-to-T) transitions at gRNA 5 and gRNA 2 target sites in different experimental conditions using hA3A fusions.
  • Conventional hA3A-BEs (hA3A-nCas9-UGI) serve as positive controls.
  • Bipartite base editors (BBEs) with zinc finger-deaminase complex binding 5′ of the Cas9 target sites show potent base editing at the respective target sites.
  • hA3A-ZF-UGI alone or BBEs targeting sites nearby show no or greatly reduced substitution rates compared to targeted BBEs.
  • SEQ ID NOs.:1-2 are shown.
  • FIG. 5 Superimposed C-to-T transitions at gRNA 2 target site comparing rAPOBEC1-fusions.
  • Conventional rAPOBEC1-BEs (BE3) serve as a positive control.
  • Bipartite base editors (BBEs) with zinc finger-deaminase complex binding 5′ of the Cas9 target sites show potent base editing at the target site.
  • rAPOBEC1-ZF-UGI alone show no base editing activity compared to targeted BBEs. SEQ ID NO:3 is shown.
  • FIG. 6 Superimposed cytosine to thymine transitions at gRNA 4 target site comparing hA3A-fusions.
  • the zinc finger-deaminase complex is oriented anti-parallel to nCas9, binding 3′ of the gRNA 4 target site.
  • the N-terminal deaminase (hA3A) is facing the 3′ end of the non-target strand (ssDNA deamination strand) which leads to a shift of C-to-T editing to the 3′ end and outside of the canonical BE1-4 editing window.
  • the spatial control of the base editing window by differential orientation/positioning of the ZF-deaminase component is shown.
  • FIGS. 7A-7D Bipartite base editors may confer enhanced product purity by flanking the editing window with UGIs and spatial separation of the nicking domain and the deaminase.
  • 7 A shows “product impurities” of conventional cytosine to thymine base editing which consist of cytosine to purine (R) byproducts as well as indels.
  • 7 B Compared to conventional deaminase-nCas9-UGI fusions (e.g.
  • BBEs containing a dual, bipartite UGI show greatly reduced cytosine to purine (R) byproducts across all cytidines of the EGFP gRNA2 target site.
  • R cytosine to purine
  • 7 C Superimposition of single bases across the gRNA2 site showing relevant deletion frequencies. Both hA3A and rAPOBEC1 bipartite base editors markedly decrease deletion frequencies back to control levels.
  • 7 D Depicting the data from C as a distribution of deletion frequencies across the target site and +/ ⁇ 25 bp flanking sites.
  • a cytidine deaminase (DA) domain and uracil glycosylase inhibitor (UGI; a small bacteriophage protein that inhibits host cell uracil DNA glycosylase (UDG), the enzyme responsible for excising uracil from the genome 1,4 ) are both fused to nCas9 (derived from either Streptococcus pyogenes Cas9 (SpCas9) or Staphylococcus aureus Cas9 (SaCas9).
  • the nCas9 forms an R-loop at a target site specified by its guide RNA (gRNA) and recognition of an adjacent protospacer adjacent motif (PAM), leaving approximately 4-8 nucleotides of the non-target strand exposed as single stranded DNA (ssDNA) near the PAM-distal end of the R-loop.
  • This region of the ssDNA is the template that is able to be deaminated by the ssDNA-specific DA domain to produce a guanosine:uracil (G:U) mismatch and defines the editing window.
  • the nCas9 nicks the non-deaminated strand of DNA, biasing conversion of the G:U mismatch to an adenine:thymine (A:T) base pair by directing the cell to repair the nick lesion using the deaminated strand as a template.
  • rAPO1 rat APOBEC1
  • AID activation-induced cytidine deaminase
  • CDA lamprey termed CDA
  • hAID human AID
  • hyperactive form of hAID lacking a nuclear export signal 1-2,5-7 a nuclear export signal
  • nSpCas9 nCas9 domain
  • any Cas9-like nickase or catalytically inactive Cas9 could be used based on any ortholog of the Cas9 protein (including the related Cpf1 enzyme class), unless specifically indicated.
  • BE in therapeutic settings will be to assess its genome-wide capacity for off-target mutagenesis and to modify the technology to minimize or, ideally, to eliminate the risks of stimulating deleterious off-target mutations.
  • BEs that can be used to reduce or eliminate potential unwanted BE mutagenesis.
  • RNA-guided nucleases e.g., nCas9, see Table 1 for a non-exhaustive list of exemplary possible fusion orthologs
  • BEs adenine deaminases
  • the main safety concern related to this technology centers around the possibility of unintended deamination of DNA.
  • ssDNA single strand DNA
  • off-target base editing takes place at known off-target binding sites of Cas9 6,7 .
  • this type of off-target is related to the targeting and binding of the nuclease, as opposed to cleavage-related off-targeting, the use of high fidelity Cas9 variants might be of limited use in this context.
  • Cas9:gRNA targeting can often tolerate off-target binding events to various degrees depending on the specific gRNA sequence, which could serve as an important source of off-target BE mutagenesis 8 .
  • SpCas9 S. pyogenes Cas9
  • HF-Cas9 high-fidelity SpCas9
  • eSpCas9 10 engineered reagents like high-fidelity SpCas9 (HF-Cas9) 9 or eSpCas9 10 may not translate to contexts where Cas9 is being used mainly as a targeting platform, as with BEs.
  • thermodynamic parameters for Cas9 binding and Cas9 cleavage are significantly different, as evidenced by the observation that very short gRNAs ( ⁇ 12-14 nts) are sufficient to target catalytically-inactive SpCas9-based transcription factor fusions to alter gene expression 11 , while gRNAs 17 nucleotides or longer are required for DNA cleavage by SpCas9 12 . Therefore, engineering BE's nSpCas9 domain to simply include the engineered HF-SpCas9 mutations may not be the optimal strategy for eliminating the capacity for BE's nSpCas9 domain to stimulate off-target deamination events.
  • TALE transcription-activator-like effector
  • ZF zinc finger array
  • a fusion between a knocked-down version of SpCas9 and a 6-finger ZF domain was shown to increase specificity of SpCas9-mediated genome editing when the ZF and gRNA are targeted to adjacent genomic sequences 14 .
  • Described herein is improved BE technology using non-R-loop-forming DNA binding domain such as aTALE or a ZF to limit the number and scope of transient R-loops and thus ssDNA exposed for deamination by BE across the genome.
  • This strategy increases the number of bases specified to include those by the gRNA in addition to the bases specified by a TALE or ZF domain (for example, addition of 3-finger ZF domain would specify ⁇ 9-10 more bases than nCas9 alone).
  • TALE domain arrays or ZF arrays are fused to the N- or C-termini of Cas9 proteins that are unable to bind efficiently to the target sequence specified by their gRNAs in human cells (see Table 2 for a list of proteins that can be used in these fusion proteins).
  • Mutations to the PAM interacting domain (PID) of the Type II-A Cas9 proteins SpCas9 or SaCas9 are sufficient to prevent these proteins from functioning efficiently in human cells without a second DNA-binding domain fusion partner 14,15 (see Table 2 for a list of PID mutations).
  • Type II-C Cas9 orthologs are an evolutionarily divergent class of Cas9 enzymes that do not possess the ability to unwind double stranded DNA 16 .
  • Cas9 orthologs are unable to cleave genomic sites in human cells when co-expressed with their cognate gRNAs; however, we have found that the added affinity of a 3-finger ZF fusion partner allows these Cas9 orthologs to bind and cleave genomic sites with high activity ( FIG. 2 ).
  • a UGI is fused either to the opposite terminus of the ZF as the nCas9 or co-expressed with the ZF-Cas9 fusion using either a self-cleaving peptide such as a 2A element or be independently translated from an internal ribosome entry site.
  • This strategy can also be used with TALE DNA binding domains in place of the ZFs. In any configuration, such configurations can be used to enhance BE fidelity by extending the functional DNA binding site specified by the targeting complex.
  • BBE Bipartite Base Editor
  • a bipartite BE (BBE) platform which includes a non-R-loop-forming DNA-binding domain (such as a ZF or a TALE) fused to a deaminase domain and an R-loop-forming Cas9 component (either catalytically inactive dCas9 or nicking nCas9 or a similarly inactive Cas9 ortholog) that are targeted to adjacent sequences as shown in FIG. 3 , can also be used to enhance BE specificity.
  • a non-R-loop-forming DNA-binding domain such as a ZF or a TALE
  • R-loop-forming Cas9 component either catalytically inactive dCas9 or nicking nCas9 or a similarly inactive Cas9 ortholog
  • binding of the deaminase-containing protein requires adjacent binding of an R-loop-forming protein to function efficiently, since deaminases (in principle, any deaminase domain listed in Table 2, or any other enzymatic domain capable of chemically mutating DNA bases, can be considered) used for base-editing are primarily active on ssDNA, which is exposed during R-loop formation.
  • This configuration can be used to increase specificity by effectively extending the overall number of DNA bases that need to be bound by the complex to mutate DNA, since each off-target binding of either the ZF- or TALE-deaminase or R-loop forming components on their own should have a reduced capacity to mutate DNA.
  • off target binding of a zinc finger-deaminase protein has a significantly reduced capacity to cause mutations compared to standard BEs since the ZF-deaminase lacks the capability to create a stable R-loop to expose ssDNA.
  • off-target binding of a dCas9 or nCas9 molecule has no capacity to stimulate unwanted deamination events on its own, since it lacks a deaminase domain, so it can be considered enzymatically inert and can only induce low-level off-target mutations through its ability to create single-stranded nicks in DNA or by exposing ssDNA to other nuclear factors as a by-product of R-loop formation.
  • nCas9 (with or without UGI) component of a BBE can bind to and nick putative off-target sites in this configuration, it cannot stimulate off-target base-editing on its own since it lacks a deaminase domain.
  • on-target deamination can be tightly controlled by co-expression/application of various nicking or catalytically inactive Cas9 variants (see Table 1 for possible orthologs), e.g., enabling different PAM preferences.
  • the genomic co-localization comes from two different proteins that are independently expressed minimizing off-targeting risk.
  • BBE bipartite base editing
  • the BBE platform offers highly optimized product purity at constant or potentially enhanced target cytosine to thymine editing efficiency with the benefit of enhanced editing window control and the prospect of reduced genome-wide Cas9-associated off-target deamination.
  • the present fusion proteins can include one, two, or more DNA binding domains such as zinc-finger nucleases, transcription activator effectors (TALEs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas RNA-guided nucleases (RGN).
  • DNA binding domains such as zinc-finger nucleases, transcription activator effectors (TALEs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas RNA-guided nucleases (RGN).
  • nCas9 and dCas9 in general, for the BBE system any R-loop forming Cas9-like enzyme that is inactive or has only nickase activity could be used, e.g., any ortholog of the Cas9 protein (including the related Cpf1 enzyme class), unless specifically indicated.
  • BV3L6 (AsCpf1) U2UMQ6 D908, 993E, Q1226, D1263 24 L. bacterium N2006 A0A182DWE3 D832A 25 (LbCpf1) *predicted based on UniRule annotation on the UniProt database. **May be determinable based on sequence alignment with other Cpf1 orthologs These orthologs, and mutants and variants thereof as known in the art, can be used in any of the fusion proteins described herein.
  • the Cas9 nuclease from S. pyogenes can be guided via simple base pair complementarity between 17-20 nucleotides of an engineered guide RNA (gRNA), e.g., a single guide RNA or crRNA/tracrRNA pair, and the complementary strand of a target genomic DNA sequence of interest that lies next to a protospacer adjacent motif (PAM), e.g., a PAM matching the sequence NGG or NAG (Shen et al., Cell Res (2013); Dicarlo et al., Nucleic Acids Res (2013); Jiang et al., Nat Biotechnol 31, 233-239 (2013); Jinek et al., Elife 2, e00471 (2013); Hwang et al., Nat Biotechnol 31, 227-229 (2013); Cong et al., Science 339, 819-823 (2013); Mali et al., Science 339, 823-826 (2013c); Cho e
  • Cpf1 The engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nuclease can also be used, e.g., as described in Zetsche et al., Cell 163, 759-771 (2015); Schunder et al., Int J Med Microbiol 303, 51-60 (2013); Makarova et al., Nat Rev Microbiol 13, 722-736 (2015); Fagerlund et al., Genome Biol 16, 251 (2015).
  • Cpf1 requires only a single 42-nt crRNA, which has 23 nt at its 3′ end that are complementary to the protospacer of the target DNA sequence (Zetsche et al., 2015).
  • SpCas9 recognizes an NGG PAM sequence that is 3′ of the protospacer
  • AsCpf1 and LbCp1 recognize TTTN PAMs that are found 5′ of the protospacer (Id.).
  • the present system utilizes a wild type or variant Cas9 protein from S. pyogenes or Staphylococcus aureus , or a wild type Cpf1 protein from Acidaminococcus sp. BV3L6 or Lachnospiraceae bacterium ND2006 either as encoded in bacteria or codon-optimized for expression in mammalian cells and/or modified in its PAM recognition specificity and/or its genome-wide specificity.
  • a number of variants have been described; see, e.g., WO 2016/141224, PCT/US2016/049147, Kleinstiver et al., Nat Biotechnol.
  • the guide RNA is expressed or present in the cell together with Cas9 or Cpf1. Either the guide RNA or the nuclease, or both, can be expressed transiently or stably in the cell or introduced as a purified protein or nucleic acid.
  • Table 2 shows potential Cas9 orthologs that can be used as chimeric proteins with ZFs or TALEs.
  • PlCas9, ClCas9, and NcCas9 are unable to efficiently bind their target sites in eukaryotic cells, while CjCas9 has substantial activity at its target sites, necessitating PAM interacting domain mutations to knock down its ability to efficiently bind its site.
  • nickase mutation residues represents a position of the enzyme either known to be required for catalytic activity of the conserved RuvC nuclease domain or predicted to be required for this catalytic activity based on sequence alignment to CjCas9 where structural information is lacking
  • the Cas9 also includes one or mutations that reduce nuclease activity of the Cas9; e.g., for SpCas9, mutations at D10A or H840A (which creates a single-strand nickase).
  • the SpCas9 variants also include mutations at one of the following amino acid positions, which destroy the nuclease activity of the Cas9: D10, E762, D839, H983, or D986 and H840 or N863, e.g., D10A/D10N and H840A/H840N/H840Y, to render the nuclease portion of the protein catalytically inactive; substitutions at these positions could be alanine (as they are in Nishimasu al., Cell 156, 935-949 (2014)), or other residues, e.g., glutamine, asparagine, tyrosine, serine, or aspartate, e.g., E762Q, H983N, H983Y, D986N, N863D, N863S, or N863H (see WO 2014/152432).
  • the fusion proteins include one or more Uracil glycosylase inhibitor (UGI) protein sequences; an exemplary UGI sequence is as follows: TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVM LLTSDAPEYKPWALVIQDSNGENKIKML (SEQ ID NO:7; Uniprot: P14739).
  • UGIs are at the C-terminal, but can also be at the N terminal, or between the components of the fusion proteins described herein. Linkers as known in the art can be used.
  • TAL effectors of plant pathogenic bacteria in the genus Xanthomonas play important roles in disease, or trigger defense, by binding host DNA and activating effector-specific host genes. Specificity depends on an effector-variable number of imperfect, typically ⁇ 33-35 amino acid repeats. Polymorphisms are present primarily at repeat positions 12 and 13, which are referred to herein as the repeat variable-diresidue (RVD).
  • RVDs of TAL effectors correspond to the nucleotides in their target sites in a direct, linear fashion, one RVD to one nucleotide, with some degeneracy and no apparent context dependence.
  • the polymorphic region that grants nucleotide specificity may be expressed as a triresidue or triplet.
  • Each DNA binding repeat can include a RVD that determines recognition of a base pair in the target DNA sequence, wherein each DNA binding repeat is responsible for recognizing one base pair in the target DNA sequence.
  • the RVD can comprise one or more of: HA for recognizing C; ND for recognizing C; HI for recognizing C; HN for recognizing G; NA for recognizing G; SN for recognizing G or A; YG for recognizing T; and NK for recognizing C and one or more of: HD for recognizing C; NG for recognizing T; NI for recognizing A; NN for recognizing G or A; NS for recognizing A or C or G or T; N* for recognizing C or T, wherein * represents a gap in the second position of the RVD; HG for recognizing T; H* for recognizing T, wherein * represents a gap in the second position of the RVD; and IG for recognizing T.
  • TALE proteins may be useful in research and biotechnology as targeted chimeric nucleases that can facilitate homologous recombination in genome engineering (e.g., to add or enhance traits useful for biofuels or biorenewables in plants). These proteins also may be useful as, for example, transcription factors, and especially for therapeutic applications requiring a very high level of specificity such as therapeutics against pathogens (e.g., viruses) as non-limiting examples.
  • pathogens e.g., viruses
  • MegaTALs are a fusion of a meganuclease with a TAL effector; see, e.g., Boissel et al., Nucl. Acids Res. 42(4):2591-2601 (2014); Boissel and Scharenberg, Methods Mol Biol. 2015; 1239:171-96.
  • Zinc finger proteins are DNA-binding proteins that contain one or more zinc fingers, independently folded zinc-containing mini-domains, the structure of which is well known in the art and defined in, for example, Miller et al., 1985, EMBO J., 4:1609; Berg, 1988, Proc. Natl. Acad. Sci. USA, 85:99; Lee et al., 1989, Science. 245:635; and Klug, 1993, Gene, 135:83.
  • Crystal structures of the zinc finger protein Zif268 and its variants bound to DNA show a semi-conserved pattern of interactions, in which typically three amino acids from the alpha-helix of the zinc finger contact three adjacent base pairs or a “subsite” in the DNA (Pavletich et al., 1991, Science, 252:809; Elrod-Erickson et al., 1998, Structure, 6:451).
  • the crystal structure of Zif268 suggested that zinc finger DNA-binding domains might function in a modular manner with a one-to-one interaction between a zinc finger and a three-base-pair “subsite” in the DNA sequence.
  • multiple zinc fingers are typically linked together in a tandem array (e.g., of 3, 4, or 6 zinc fingers) to achieve sequence-specific recognition of a contiguous DNA sequence (Klug, 1993, Gene 135:83).
  • Such recombinant zinc finger proteins can be fused to functional domains, such as transcriptional activators, transcriptional repressors, methylation domains, and nucleases to regulate gene expression, alter DNA methylation, and introduce targeted alterations into genomes of model organisms, plants, and human cells (Carroll, 2008, Gene Ther., 15:1463-68; Cathomen, 2008, Mol. Ther., 16:1200-07; Wu et al., 2007, Cell. Mol. Life Sci., 64:2933-44).
  • functional domains such as transcriptional activators, transcriptional repressors, methylation domains, and nucleases to regulate gene expression, alter DNA methylation, and introduce targeted alterations into genomes of model organisms, plants, and human cells
  • module assembly One existing method for engineering zinc finger arrays, known as “modular assembly,” advocates the simple joining together of pre-selected zinc finger modules into arrays (Segal et al., 2003, Biochemistry, 42:2137-48; Beerli et al., 2002, Nat. Biotechnol., 20:135-141; Mandell et al., 2006, Nucleic Acids Res., 34:W516-523; Carroll et al., 2006, Nat. Protoc. 1:1329-41; Liu et al., 2002, J. Biol. Chem., 277:3850-56; Bae et al., 2003, Nat. Biotechnol., 21:275-280; Wright et al., 2006, Nat.
  • the base editor is a fusion of a DNA-binding domain to a deaminase, or an active portion thereof, that modifies cytosine DNA bases, e.g., a cytidine deaminase from the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) family of deaminases, including APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4 (see, e.g., Yang et al., J Genet Genomics.
  • a cytidine deaminase from the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) family of deaminases, including APOBEC1, APOBEC2, APOB
  • activation-induced cytidine deaminase AID
  • activation-induced cytidine deaminase AID
  • AICDA activation induced cytidine deaminase
  • CDA1 cytosine deaminase 1
  • CDA2 cytosine deaminase acting on tRNA
  • Table 2 provides exemplary sequences; other sequences can also be used.
  • the components of the fusion proteins are at least 80%, e.g., at least 85%, 90%, 95%, 97%, or 99% identical to the amino acid sequence of a exemplary sequence (e.g., as provided herein), e.g., have differences at up to 5%, 10%, 15%, or 20% of the residues of the exemplary sequence replaced, e.g., with conservative mutations, in addition to the mutations described herein.
  • the variant retains desired activity of the parent, e.g., in the case of a Cas9 variant or fragment, nickase activity or no nuclease activity, and/or the ability to interact with a guide RNA and/or target DNA, or deaminase activity in the case of a deaminase variant or active portion thereof.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • the length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%.
  • the nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • nucleic acid “identity” is equivalent to nucleic acid “homology”.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. Percent identity between two polypeptides or nucleic acid sequences is determined in various ways that are within the skill in the art, for instance, using publicly available computer software such as Smith Waterman Alignment (Smith, T. F. and M. S.
  • the length of comparison can be any length, up to and including full length (e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%).
  • full length e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%.
  • at least 80% of the full length of the sequence is aligned.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
  • Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
  • isolated nucleic acids encoding the bipartite deaminase fusion proteins
  • vectors comprising the isolated nucleic acids, optionally operably linked to one or more regulatory domains for expressing the variant proteins
  • host cells e.g., mammalian host cells, comprising the nucleic acids, and optionally expressing the variant proteins.
  • the host cells are stem cells, e.g., hematopoietic stem cells.
  • the bipartite deaminase fusion proteins described herein can be used for altering the genome of a cell.
  • the methods generally include expressing or contacting the fusion proteins in the cells; in versions using one or two Cas9s, the methods include using a guide RNA having a region complementary to a selected portion of the genome of the cell.
  • Methods for selectively altering the genome of a cell are known in the art, see, e.g., U.S. Pat. No. 8,993,233; US 20140186958; U.S. Pat. No.
  • CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
  • the fusion proteins include a linker between the DNA binding domain (e.g., ZFN, TALE, or nCas9) and the BE domains.
  • Linkers that can be used in these fusion proteins (or between fusion proteins in a concatenated structure) can include any sequence that does not interfere with the function of the fusion proteins.
  • the linkers are short, e.g., 2-20 amino acids, and are typically flexible (i.e., comprising amino acids with a high degree of freedom such as glycine, alanine, and serine).
  • the linker comprises one or more units consisting of GGGS (SEQ ID NO:8) or GGGGS (SEQ ID NO:9), e.g., two, three, four, or more repeats of the GGGS (SEQ ID NO:8) or GGGGS (SEQ ID NO:9) unit.
  • Other linker sequences can also be used.
  • the fusion protein includes a cell-penetrating peptide sequence that facilitates delivery to the intracellular space, e.g., HIV-derived TAT peptide, penetratins, transportans, or hCT derived cell-penetrating peptides, see, e.g., Caron et al., (2001) Mol Ther. 3(3):310-8; Langel, Cell-Penetrating Peptides: Processes and Applications (CRC Press, Boca Raton Fla. 2002); El-Andaloussi et al., (2005) Curr Pharm Des. 11(28):3597-611; and Deshayes et al., (2005) Cell Mol Life Sci. 62(16):1839-49.
  • a cell-penetrating peptide sequence that facilitates delivery to the intracellular space, e.g., HIV-derived TAT peptide, penetratins, transportans, or hCT derived cell-penetrating peptides, see
  • CPPs Cell penetrating peptides
  • cytoplasm or other organelles e.g. the mitochondria and the nucleus.
  • molecules that can be delivered by CPPs include therapeutic drugs, plasmid DNA, oligonucleotides, siRNA, peptide-nucleic acid (PNA), proteins, peptides, nanoparticles, and liposomes.
  • CPPs are generally 30 amino acids or less, are derived from naturally or non-naturally occurring protein or chimeric sequences, and contain either a high relative abundance of positively charged amino acids, e.g.
  • CPPs that are commonly used in the art include Tat (Frankel et al., (1988) Cell. 55:1189-1193, Vives et al., (1997) J. Biol. Chem. 272:16010-16017), penetratin (Derossi et al., (1994) J. Biol. Chem. 269:10444-10450), polyarginine peptide sequences (Wender et al., (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008, Futaki et al., (2001) J. Biol. Chem. 276:5836-5840), and transportan (Pooga et al., (1998) Nat. Biotechnol. 16:857-861).
  • CPPs can be linked with their cargo through covalent or non-covalent strategies.
  • Methods for covalently joining a CPP and its cargo are known in the art, e.g. chemical cross-linking (Stetsenko et al., (2000) J. Org. Chem. 65:4900-4909, Gait et al. (2003) Cell. Mol. Life. Sci. 60:844-853) or cloning a fusion protein (Nagahara et al., (1998) Nat. Med. 4:1449-1453).
  • Non-covalent coupling between the cargo and short amphipathic CPPs comprising polar and non-polar domains is established through electrostatic and hydrophobic interactions.
  • CPPs have been utilized in the art to deliver potentially therapeutic biomolecules into cells. Examples include cyclosporine linked to polyarginine for immunosuppression (Rothbard et al., (2000) Nature Medicine 6(11): 1253-1257), siRNA against cyclin B1 linked to a CPP called MPG for inhibiting tumorigenesis (Crombez et al., (2007) Biochem Soc. Trans. 35:44-46), tumor suppressor p53 peptides linked to CPPs to reduce cancer cell growth (Takenobu et al., (2002) Mol. Cancer Ther. 1(12):1043-1049, Snyder et al., (2004) PLoS Biol. 2:E36), and dominant negative forms of Ras or phosphoinositol 3 kinase (PI3K) fused to Tat to treat asthma (Myou et al., (2003) J. Immunol. 171:4399-4405).
  • PI3K phosphoinositol 3
  • CPPs have been utilized in the art to transport contrast agents into cells for imaging and biosensing applications.
  • green fluorescent protein (GFP) attached to Tat has been used to label cancer cells (Shokolenko et al., (2005) DNA Repair 4(4):511-518).
  • Tat conjugated to quantum dots have been used to successfully cross the blood-brain barrier for visualization of the rat brain (Santra et al., (2005) Chem. Commun. 3144-3146).
  • CPPs have also been combined with magnetic resonance imaging techniques for cell imaging (Liu et al., (2006) Biochem. and Biophys. Res. Comm. 347(1):133-140). See also Ramsey and Flynn, Pharmacol Ther. 2015 Jul. 22. pii: S0163-7258(15)00141-2.
  • the fusion proteins can include a nuclear localization sequence, e.g., SV40 large T antigen NLS (PKKKRRV (SEQ ID NO: 10)) and nucleoplasmin NLS (KRPAATKKAGQAKKKK (SEQ ID NO: 11)).
  • PKKKRRV SEQ ID NO: 10
  • KRPAATKKAGQAKKKK SEQ ID NO: 11
  • Other NLSs are known in the art; see, e.g., Cokol et al., EMBO Rep. 2000 Nov. 15; 1(5): 411-415; Freitas and Cunha, Curr Genomics. 2009 December; 10(8): 550-557.
  • the fusion proteins include a moiety that has a high affinity for a ligand, for example GST, FLAG or hexahistidine sequences.
  • affinity tags can facilitate the purification of recombinant fusion proteins.
  • the proteins can be produced using any method known in the art, e.g., by in vitro translation, or expression in a suitable host cell from nucleic acid encoding the fusion protein; a number of methods are known in the art for producing proteins.
  • the proteins can be produced in and purified from yeast, E. coli , insect cell lines, plants, transgenic animals, or cultured mammalian cells; see, e.g., Palomares et al., “Production of Recombinant Proteins: Challenges and Solutions,” Methods Mol Biol. 2004; 267:15-52.
  • the fusion proteins can be linked to a moiety that facilitates transfer into a cell, e.g., a lipid nanoparticle, optionally with a linker that is cleaved once the protein is inside the cell. See, e.g., LaFountaine et al., Int J Pharm. 2015 Aug. 13; 494(1):180-194.
  • the nucleic acid encoding the fusion can be cloned into an intermediate vector for transformation into prokaryotic or eukaryotic cells for replication and/or expression.
  • Intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors, or insect vectors, for storage or manipulation of the nucleic acid encoding the fusion for production of the fusion protein.
  • the nucleic acid encoding the fusion protein can also be cloned into an expression vector, for administration to a plant cell, animal cell, preferably a mammalian cell or a human cell, fungal cell, bacterial cell, or protozoan cell.
  • a sequence encoding a fusion protein is typically subcloned into an expression vector that contains a promoter to direct transcription.
  • Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual (3d ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 2010).
  • Bacterial expression systems for expressing the engineered protein are available in, e.g., E. coli, Bacillus sp., and Salmonella (Palva et al., 1983, Gene 22:229-235). Kits for such expression systems are commercially available.
  • Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.
  • the promoter used to direct expression of a nucleic acid depends on the particular application. For example, a strong constitutive promoter is typically used for expression and purification of fusion proteins. In contrast, when the fusion protein is to be administered in vivo for gene regulation, either a constitutive or an inducible promoter can be used, depending on the particular use of the fusion protein. In addition, a preferred promoter for administration of the fusion protein can be a weak promoter, such as HSV TK or a promoter having similar activity.
  • the promoter can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Gal4 response elements, lac repressor response element, and small molecule control systems such as tetracycline-regulated systems and the RU-486 system (see, e.g., Gossen & Bujard, 1992, Proc. Natl. Acad. Sci. USA, 89:5547; Oligino et al., 1998, Gene Ther., 5:491-496; Wang et al., 1997, Gene Ther., 4:432-441; Neering et al., 1996, Blood, 88:1147-55; and Rendahl et al., 1998, Nat. Biotechnol., 16:757-761).
  • elements that are responsive to transactivation e.g., hypoxia response elements, Gal4 response elements, lac repressor response element, and small molecule control systems such as tetracycline-regulated systems and the RU-486 system
  • the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic.
  • a typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence encoding the fusion protein, and any signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination. Additional elements of the cassette may include, e.g., enhancers, and heterologous spliced intronic signals.
  • the particular expression vector used to transport the genetic information into the cell is selected with regard to the intended use of the fusion protein, e.g., expression in plants, animals, bacteria, fungus, protozoa, etc.
  • Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and commercially available tag-fusion expression systems such as GST and LacZ.
  • Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus.
  • eukaryotic vectors include pMSG pAV009/A+, pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
  • the vectors for expressing the fusion protein can include RNA Pol III promoters to drive expression of the guide RNAs, e.g., the HI, U6 or 7SK promoters. These human promoters allow for expression of fusion protein in mammalian cells following plasmid transfection.
  • Some expression systems have markers for selection of stably transfected cell lines such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase.
  • High yield expression systems are also suitable, such as using a baculovirus vector in insect cells, with the gRNA encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.
  • the elements that are typically included in expression vectors also include a replicon that functions in E. coli , a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of recombinant sequences.
  • Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of protein, which are then purified using standard techniques (see, e.g., Colley et al., 1989, J. Biol. Chem., 264:17619-22; Guide to Protein Purification, in Methods in Enzymology, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (see, e.g., Morrison, 1977, J. Bacteriol. 132:349-351; Clark-Curtiss & Curtiss, Methods in Enzymology 101:347-362 (Wu et al., eds, 1983).
  • Any of the known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, nucleofection, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both episomal and integrative, and any of the other well-known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the fusion protein.
  • the methods can include delivering the fusion protein and guide RNA together, e.g., as a complex.
  • the fusion protein and gRNA can be can be overexpressed in a host cell and purified, then complexed with the guide RNA (e.g., in a test tube) to form a ribonucleoprotein (RNP), and delivered to cells.
  • the fusion protein can be expressed in and purified from bacteria through the use of bacterial expression plasmids.
  • His-tagged fusion protein can be expressed in bacterial cells and then purified using nickel affinity chromatography.
  • RNPs circumvents the necessity of delivering plasmid DNAs encoding the nuclease or the guide, or encoding the nuclease as an mRNA. RNP delivery may also improve specificity, presumably because the half-life of the RNP is shorter and there's no persistent expression of the nuclease and guide (as you'd get from a plasmid).
  • the RNPs can be delivered to the cells in vivo or in vitro, e.g., using lipid-mediated transfection or electroporation. See, e.g., Liang et al.
  • the present invention also includes the vectors and cells comprising the vectors, as well as kits comprising the proteins and nucleic acids described herein, e.g., for use in a method described herein.
  • Expression plasmids were constructed by selectively amplifying desired DNA sequences using the PCR method such that they had significant overlapping ends and using isothermal assembly (or “Gibson Assembly”, NEB) to assemble them in the desired order in a pCAG expression vector.
  • PCR was conducted using Q5 or Phusion polymerases (NEB).
  • Cas9 gRNAs were cloned using the pUC 19-based entry vector BPK 1520 (via BsmBI cassette) under control of a U6 promoter.
  • HEK293 cell line in which an integrated EGFP reporter gene has been integrated was grown in culture using media consisting of Advanced Dulbeccos Modified Medium (Gibco) supplemented with 10% FBS (Gibco), 1% 10,000 U/ml penicillin-streptomycin solution (Gibco), and 1% Glutamax (Gibco). Cells were passaged every 3-4 days to maintain an actively growing population and avoid anoxic conditions.
  • Transfections containing 800 nanogram of transfection quality DNA (Qiagen Maxi- or Miniprep) encoding desired proteins/gRNAs were conducted by seeding 1 ⁇ 10 5 cells in 24-well TC-treated plates and using TransIT-293 reagent according to manufacturer's protocol (Mirus Bio). gDNA was harvested 3 days post-transfection using the DNAdvance kit (Agencourt). U2OS.EGFP cells containing a single stably integrated copy of the EGFP-PEST reporter gene and HEK293T cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM GlutaMax, penicillin and streptomycin at 37° C. with 5% C02.
  • U2OS.EGFP cells The media for U2OS.EGFP cells was supplemented with 400 ⁇ g ml ⁇ 1 Geneticin. Cell line identity was validated by STR profiling (ATCC), and cells were tested regularly for mycoplasma contamination.
  • U2OS.EGFP cells were transfected with 750 ng of plasmid expressing BE and 250 ng of plasmid expressing gRNA according to the manufacturer's recommendations using the DN-100 program and SE cell line kit on a Lonza 4-D Nucleofector. Disruption of the EGFP gene was evaluated using flow cytometry 48 hours post-transfection.
  • Target site genomic DNA was amplified using gene-specific DNA primers flanking desired target sequence.
  • Illumina TruSeq adapters were added to the ends of the amplicons either by PCR or NEBNext Ultra II kit (NEB) and molecularly indexed with NEBNext Dual Index Primers (NEB). Samples were combined into libraries and sequenced on the Illumina MiSeq machine using the MiSeq Reagent Micro Kit v2 (Illumina). Sequencing results were analyzed using a batch version of the software CRISPResso (crispresso.rocks).
  • aureus Cas9 (SEQ ID NO: 20) MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHS ELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDG EVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEE LRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFT NLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILD
  • lavamentivorans Cas9 (SEQ ID NO: 22) MERIFGFDIGTTSIGFSVIDYSSTQSAGNIQRLGVRIFPEARDPDGTPLNQQRRQKRMMRRQLRRRRIRRKALNETLHEAG FLPAYGSADWPVVMADEPYELRRRGLEEGLSAYEFGRAIYHLAQHRHFKGRELEESDTPDPDVDDEKEAANERAATLKALK NEQTTLGAWLARRPPSDRKRGIHAHRNVVAEEFERLWEVQSKFHPALKSEEMRARISDTIFAQRPVFWRKNTLGECRFMPG EPLCPKGSWLSQQRRMLEKLNNLAIAGGNARPLDAEERDAILSKLQQQASMSWPGVRSALKALYKQRGEPGAEKSLKFNLE LGGESKLLGNALEAKLADMFGPDWPAHPRKQEIRHAVHERLWAADYGETPDKKRVIILSEKDRKAHREAAANSFVADFGIT GEQAAQLQALKLPTGW
  • cinerea Cas9 (SEQ ID NO: 23) MAAFKPNPMNYILGLDIGIASVGWAIVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAAARRLARSVRRLTRRRAHRLLR ARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGV ADNTHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFNRKDLQAELNLLFEKQKEFGNPHVSDGLKEGIETLLMTQR PALSGDAVQKMLGHCTFEPTEPKAAKNTYTAERFVWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLL DLDDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRVQP EILEALLKHISFDKFVQISLKALRRIVPLMEQ
  • nCas9-Uracil DNA Glycosylase inhibitor (UGI) targeted to adjacent sequences.
  • UGI nCas9-Uracil DNA Glycosylase inhibitor
  • An nCas9-UGI architecture mimics the standard BE3 architecture that is known to be an important part of a functional BE protein.
  • a second UGI to enhance product purity we fused a UGI to both the ZF (via LRGS linker) as well as the nCas9 (same linker as in conventional BE3) C-terminus 17 .
  • both rAPOBEC1 and hAPOBEC3A BBEs are able to stimulate efficient base-editing at rates similar to or greater than monomeric BE counterparts (of the form deaminase-nCas9-UGI). ( FIGS. 4-6 ). This effect is consistent regardless of the orientation of the two components with respect to each other and works using multiple different ZFs or gRNAs.
  • the BBE When the ZF-deaminase fusion was targeted upstream (toward the 5′ end) of the nCas9 site, the BBE mutated cytosines in a similar “editing window” as those described for conventional BEs and with a similar distribution ( FIGS. 4 and 5 ).
  • the BBE When the ZF-deaminase is positioned 8 basepairs downstream of the nCas9 site, the BBE has a much broader editing window that shifts towards the 3′ end of the gRNA target site, suggesting a possible control of the editing window by programmed proximity of the deaminase-containing bipartite “half”. This editing window flexibility adds spatial control to the bipartite base editing circuitry ( FIG. 6 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are fusion proteins useful in a bipartite cytosine base editor system comprising: (i) a first fusion protein comprising a non-R-loop-forming programmable DNA binding domain, preferably a transcription-activator-like effector (TALE) or zinc finger array (ZF), fused to a deaminase enzyme, or an active portion thereof, optionally with a linker therebetween, or (ii) a second fusion protein comprising an R-loop-forming Cas9 protein that lacks nuclease activity or is a nickase, but can interact with a guide RNA and target DNA, fused to a Uracil glycosylase inhibitor (UGI), optionally with a linker therebetween. Additionally, provided are methods for targeted deamination of one or more selected cytosines in a nucleic acid.

Description

    CLAIM OF PRIORITY
  • This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/511,296, filed on May 25, 2017; Ser. No. 62/541,544, filed on Aug. 4, 2017; and Ser. No. 62/622,676, filed on Jan. 26, 2018. The entire contents of the foregoing are hereby incorporated by reference.
    • FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • This invention was made with Government support under Grant No. GM118158 awarded by the National Institutes of Health. The Government has certain rights in the invention.
    • TECHNICAL FIELD
  • Described herein are methods and compositions for improving the genome-wide specificities of targeted base editing technologies.
    • BACKGROUND
  • Base editing (BE) technology is based on the fusion of a DNA binding domain as e.g. catalytically inactive or nicking Cas9 (dCas9 or nCas9) to a cytidine or adenine deaminase and a uracil glycosylase inhibitor (UGI). These fusion proteins allow for R-loop formation and deamination of cytosine or adenine at a specific genomic locus introducing targeted substitutions (C/G→T/A or A/T→G/C)1-4. Precise and efficient correction of single nucleotide variants might yield substantial therapeutic benefits, specifically as the current approach of double-strand break (DSB) based donor template integration via homology directed repair (HDR) is inefficient and not feasible in post-mitotic cells5. Since the deaminases used for cytosine-to-thymine conversion require an ssDNA substrate, nCas9-meditated R-loop formation, which leaves the nCas9 non-target strand single-stranded, is a critical factor in BE targeting success1.
    • SUMMARY
  • CRISPR base editor platforms (BE) possess the unique capability to generate precise, user-defined genome-editing events without the need for a donor DNA molecule. Base editors (BEs) that include a single strand nicking CRISPR-Cas9 (nCas9) protein fused to a cytidine deaminase domain and uracil glycosylase inhibitor (UGI) (BE3) efficiently induce cytosine-to-thymine (C-to-T) base transitions in a site-specific manner as determined by the CRISPR guide RNA (gRNA) spacer sequence1. As with all genome editing reagents, it is critical to first determine and then mitigate BE's capacity for generating off-target mutations before it is used for therapeutics so as to limit its potential for creating deleterious and irreversible genetically-encoded side-effects. Herein, we describe bipartite BEs (BBEs) that rely on the use of adjacently-targeting DNA binding domains to properly function. Unlike previously-described BEs that contain machinery to both deaminate and form R-loops in a monomeric unit, we describe a system where these two critical functions are separated onto two proteins that must work together to stimulate robust deamination. To do so, we fused engineered zinc-fingers (ZFs) to deaminase enzymes (ZF-deaminase) and targeted it adjacent to an nCas9-UGI binding site, thereby reconstituting the full functionality of a BE around adjacently-targeting DNA sequences and stimulating robust DNA modification. Since efficient activity of this bipartite enzyme relies on the specific adjacent binding of two separate DNA-binding domains, it should increase the specificity of base editing by decreasing the ability of its constituent pieces to function robustly at any of their off-target binding sites in genomic DNA, so long as adjacent binding of the two constituents does not occur at that site. Spatially separating nCas9 from the deaminase domain should also reduce the synergistically induced indel formation adjacent to and at the site of targeted base editing, thereby enhancing overall product purity and off-target indel formation.
  • While some Cas9 orthologs and variants may be deficient for CRISPR-mediated DNA-binding and genome- or base editing (such as PAM-interacting deficient (PID) mutants or type-II-C Cas9s14-16), we noted that rescuing their DNA-targeting capabilities by fusing them to an adjacently-targeted engineered DNA binding domain such as a ZF or a TALE may allow them to constitute the basis of BEs with better specificity profiles than those described as yet in the literature. By requiring the adjacent binding of the two DNA binding domains (the ZF or TALE and the deficient Cas9 variant or ortholog, the resulting protein specifies a total DNA target sequence comprising both target sites, increasing the number of total bases specified by the complex and thereby imparting greater overall specificity to the technique. Use of these proteins as the basis of base editors would therefore constitute a more specific base editing platform. Thus, provided herein are fusion proteins useful in a bipartite cytosine base editor system comprising: (i) a first fusion protein comprising a non-R-loop-forming programmable DNA binding domain, preferably a transcription-activator-like effector (TALE) or zinc finger array (ZF), fused to a deaminase enzyme, or an active portion thereof, optionally with a linker therebetween, or (ii) a second fusion protein comprising an R-loop-forming Cas9 protein that lacks nuclease activity or is a nickase, but can interact with a guide RNA and target DNA, fused to a Uracil glycosylase inhibitor (UGI), optionally with a linker therebetween.
  • In some embodiments, the first fusion protein comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
  • In some embodiments, the second fusion protein comprises an SpCas9 nickase or inactive nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or an inactive Cpf1 (dCpf1) protein. In some embodiments, the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
  • In some embodiments, the DNA binding domain comprises a zinc finger DNA binding array.
  • Also described herein are monomeric fusion proteins comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, and optionally (iv) a fourth portion comprising a Uracil DNA glycosylase inhibitor (UGI), optionally with peptide linkers in between some or all of the first, second, third, or fourth portions, and wherein the domains (i)-(iv) can be in any order.
  • Further provided herein are fusion proteins comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, such as type-II-C Cas9 orthologs or similarly deficient species, and (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, optionally with peptide linkers in between some or all of the first, second, or third portions, and wherein the domains (i)-(iii) can be in any order. These fusion proteins can be used in combination with a protein comprising a Uracil DNA glycosylase inhibitor (UGI), e.g., in the methods described herein.
  • In some embodiments, the first portion comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
  • In some embodiments, the second portion comprises an SpCas9 nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or a type-II-C Cas9 ortholog. In some embodiments, the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
  • In some embodiments, the second portion comprises PlCas9, ClCas9, or NcCas9; or SpCas9, SaCas9, or CjCas9 with a mutations to a PAM interacting domain (PID), e.g., as shown in Table 2.
  • In some embodiments, the DNA binding domain comprises a zinc finger DNA binding array.
  • Also provided herein are compositions comprising a purified fusion protein described herein, optionally further comprising a guide RNA that interacts with the Cas9 portion of the fusion protein. In some embodiments, the composition includes one or more ribonucleoprotein (RNP) complexes.
  • Further provided herein are nucleic acids encoding the fusion proteins described herein, vectors comprising the nucleic acids, and isolated host cells comprising and/or expressing the fusion proteins.
  • Also provided are compositions comprising a nucleic acid encoding the fusion proteins described herein.
  • Additionally, provided are methods for targeted deamination of one or more selected cytosines in a nucleic acid. The methods include contacting the nucleic acid with fusion proteins described herein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to (e.g., within 1, 2, 5, 10, 15, or 20 nts of) the selected cytosines. In some embodiments, the nucleic acid is in a cell, preferably a eukaryotic cell.
  • Also provided herein are methods for targeted deamination of a nucleic acid in a cell. The methods include expressing in the cell, or contacting the cell with, the fusion proteins described herein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to (e.g., within 1, 2, 5, 10, 15, or 20 nts of) the selected cytosine.
  • In some embodiments, the fusion protein is delivered as an RNP, or as an mRNA or plasmid comprising a sequence encoding the fusion protein.
  • Also provided herein are ribonucleoprotein (RNP) complexes that include a variant SpCas9 protein as described herein and a guide RNA that targets a sequence having a PAM sequence targeted by the bipartite deaminase fusion protein comprising Cas9.
  • Also provided herein are methods for targeted deamination, or improving specificity of targeted deamination, of a selected cytosine in a nucleic acid, comprising contacting the nucleic acid with one or more of the fusion proteins or base editing systems described herein. In some embodiments, the fusion protein is delivered as an RNP, or as an mRNA or plasmid comprising a sequence encoding a fusion protein described herein.
  • Also provided herein are methods for deaminating a selected cytosine in a nucleic acid, the method comprising contacting the nucleic acid with a fusion protein or base editing system described herein.
  • Additionally, provided herein are compositions comprising a purified a fusion protein or base editing system as described herein.
  • Further, provided herein are nucleic acids encoding a fusion protein or base editing system described herein, as well as vectors comprising the nucleic acids, and host cells comprising the nucleic acids, e.g., stem cells, e.g., hematopoietic stem cells.
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
  • Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.
    • DESCRIPTION OF DRAWINGS
  • FIG. 1. Cas9 PID mutants or Type II-C Cas9s as chimeric BE technologies with ZFs. The 6-finger zinc finger array and UGI are fused to the C-terminus of nCas9 and any of the wild type or engineered deaminase domains is fused to the N-terminus of the nCas9. The ZF binding sequence is directly adjacent to the gRNA target site. In this model, binding of the ZF is a prerequisite for formation of the R-loop by nCas9, greatly reducing the number of possible off-target sites at which R-loops might be formed to those that are adjacent to a ZF binding site. The analogous strategy using TALEs instead of ZFs is also described herein.
  • FIG. 2. Type II-C Cas9s demonstrate increased binding and nuclease activity at their target sites in human cells when fused to 3-finger ZFs. In this assay, a chromosomally-integrated EGFP gene is used as a reporter for binding (via steric hindrance of transcription) or nuclease activity (via NHEJ-mediated small insertion and deletions in the coding sequence). Transient transfection of plasmids expressing various Cas9 orthologs and gRNAs with 20- or 23-nucleotide homology to the EGFP reporter results in disruption or repression of EGFP, resulting in EGFP-negative cells when assayed by flow cytometry. In all cases, addition of a ZF fusion partner increases the EGFP disruption rate of the Cas9 ortholog tested. Notably, addition of a ZF fusion partner to PlCas9 increases EGFP disruption activity of this ortholog from background levels to 85%.
  • FIG. 3. Diagram of a bipartite base editing architecture. A nicking Cas9 (nCas9) is targeted to the deamination site by a guide RNA (gRNA). Subsequent R-loop formation produces an ssDNA editing window on the DNA strand that is not bound by nCas9 (deaminated strand). The zinc finger-deaminase complex targets dsDNA near the formed R-loop. Target cytosines in the editing window get deaminated. Nicking Cas9 induces a single strand break (SSB) in the genomic DNA (non-deaminated strand) thus attracting DNA repair proteins, e.g. involving the mismatch repair (MMR) pathway. As the edited target cytosine is converted to a uracil and the deaminated strand serves as a template for the nicked (undeaminated) strand repair is biased towards the intended cytosine to thymine transition.
  • FIG. 4. Superimposed cytosine to thymine (C-to-T) transitions at gRNA 5 and gRNA 2 target sites in different experimental conditions using hA3A fusions. Conventional hA3A-BEs (hA3A-nCas9-UGI) serve as positive controls. Bipartite base editors (BBEs) with zinc finger-deaminase complex binding 5′ of the Cas9 target sites show potent base editing at the respective target sites. hA3A-ZF-UGI alone or BBEs targeting sites nearby show no or greatly reduced substitution rates compared to targeted BBEs. SEQ ID NOs.:1-2 are shown.
  • FIG. 5. Superimposed C-to-T transitions at gRNA 2 target site comparing rAPOBEC1-fusions. Conventional rAPOBEC1-BEs (BE3) serve as a positive control. Bipartite base editors (BBEs) with zinc finger-deaminase complex binding 5′ of the Cas9 target sites show potent base editing at the target site. rAPOBEC1-ZF-UGI alone show no base editing activity compared to targeted BBEs. SEQ ID NO:3 is shown.
  • FIG. 6. Superimposed cytosine to thymine transitions at gRNA 4 target site comparing hA3A-fusions. In contrast to previous experiments, the zinc finger-deaminase complex is oriented anti-parallel to nCas9, binding 3′ of the gRNA 4 target site. Thus the N-terminal deaminase (hA3A) is facing the 3′ end of the non-target strand (ssDNA deamination strand) which leads to a shift of C-to-T editing to the 3′ end and outside of the canonical BE1-4 editing window. The spatial control of the base editing window by differential orientation/positioning of the ZF-deaminase component is shown. SEQ ID NO:6 is shown.
  • FIGS. 7A-7D. Bipartite base editors may confer enhanced product purity by flanking the editing window with UGIs and spatial separation of the nicking domain and the deaminase. (7A) shows “product impurities” of conventional cytosine to thymine base editing which consist of cytosine to purine (R) byproducts as well as indels. (7B) Compared to conventional deaminase-nCas9-UGI fusions (e.g. BE3 or hA3A-nCas9-UGI), BBEs containing a dual, bipartite UGI show greatly reduced cytosine to purine (R) byproducts across all cytidines of the EGFP gRNA2 target site. (7C) Superimposition of single bases across the gRNA2 site showing relevant deletion frequencies. Both hA3A and rAPOBEC1 bipartite base editors markedly decrease deletion frequencies back to control levels. (7D) Depicting the data from C as a distribution of deletion frequencies across the target site and +/−25 bp flanking sites.
    •  DETAILED DESCRIPTION
  • In the most efficient BE configuration described to date, a cytidine deaminase (DA) domain and uracil glycosylase inhibitor (UGI; a small bacteriophage protein that inhibits host cell uracil DNA glycosylase (UDG), the enzyme responsible for excising uracil from the genome1,4) are both fused to nCas9 (derived from either Streptococcus pyogenes Cas9 (SpCas9) or Staphylococcus aureus Cas9 (SaCas9). The nCas9 forms an R-loop at a target site specified by its guide RNA (gRNA) and recognition of an adjacent protospacer adjacent motif (PAM), leaving approximately 4-8 nucleotides of the non-target strand exposed as single stranded DNA (ssDNA) near the PAM-distal end of the R-loop. This region of the ssDNA is the template that is able to be deaminated by the ssDNA-specific DA domain to produce a guanosine:uracil (G:U) mismatch and defines the editing window. The nCas9 nicks the non-deaminated strand of DNA, biasing conversion of the G:U mismatch to an adenine:thymine (A:T) base pair by directing the cell to repair the nick lesion using the deaminated strand as a template. To date, the DA domains described in these fusion proteins have been rat APOBEC1 (rAPO1), an activation-induced cytidine deaminase (AID) derived from lamprey termed CDA (PmCDA), human AID (hAID), or a hyperactive form of hAID lacking a nuclear export signal1-2,5-7. BE technology was primarily established using the SpCas9 protein for its nCas9 domain (nSpCas9), but although herein we refer to nCas9, in general any Cas9-like nickase or catalytically inactive Cas9 could be used based on any ortholog of the Cas9 protein (including the related Cpf1 enzyme class), unless specifically indicated.
  • An important consideration for the use of BE in therapeutic settings will be to assess its genome-wide capacity for off-target mutagenesis and to modify the technology to minimize or, ideally, to eliminate the risks of stimulating deleterious off-target mutations. Herein, we described technological improvements to BEs that can be used to reduce or eliminate potential unwanted BE mutagenesis.
  • Zinc-Finger/Cas9 Fusion Proteins Limit Off-Target Binding and Deamination
  • While the fusion of RNA-guided nucleases (e.g., nCas9, see Table 1 for a non-exhaustive list of exemplary possible fusion orthologs) to cytidine or adenine deaminases (BEs) has been proven to be an efficient tool, the main safety concern related to this technology centers around the possibility of unintended deamination of DNA. While unbiased genome-wide detection of Cas9-independent deaminase activity on single strand DNA (ssDNA) is lacking, recently published data suggests off-target base editing takes place at known off-target binding sites of Cas96,7. As this type of off-target is related to the targeting and binding of the nuclease, as opposed to cleavage-related off-targeting, the use of high fidelity Cas9 variants might be of limited use in this context.
  • Importantly, Cas9:gRNA targeting can often tolerate off-target binding events to various degrees depending on the specific gRNA sequence, which could serve as an important source of off-target BE mutagenesis8. While efforts to engineer S. pyogenes Cas9 (SpCas9) to increase its specificity as a nuclease have been largely successful, the specificity advantages of engineered reagents like high-fidelity SpCas9 (HF-Cas9)9 or eSpCas910 may not translate to contexts where Cas9 is being used mainly as a targeting platform, as with BEs. It is widely thought that the thermodynamic parameters for Cas9 binding and Cas9 cleavage are significantly different, as evidenced by the observation that very short gRNAs (˜12-14 nts) are sufficient to target catalytically-inactive SpCas9-based transcription factor fusions to alter gene expression11, while gRNAs 17 nucleotides or longer are required for DNA cleavage by SpCas912. Therefore, engineering BE's nSpCas9 domain to simply include the engineered HF-SpCas9 mutations may not be the optimal strategy for eliminating the capacity for BE's nSpCas9 domain to stimulate off-target deamination events.
  • One strategy to reduce off-target deamination events is to restrict nCas9 binding and R-loop formation to gRNA sites that are directly adjacent to a transcription-activator-like effector (TALE) or zinc finger array (ZF) binding site (FIG. 3) whose cognate TALE or ZF has been incorporated into the BE architecture. Several groups have described “traditional” double-strand-break inducing genome-editing reagents that make use of an extra engineered DNA binding domain in addition to what is usually considered necessary to increase overall specificity of the fusion protein13,14. Notably, a fusion between a knocked-down version of SpCas9 and a 6-finger ZF domain was shown to increase specificity of SpCas9-mediated genome editing when the ZF and gRNA are targeted to adjacent genomic sequences14. Described herein is improved BE technology using non-R-loop-forming DNA binding domain such as aTALE or a ZF to limit the number and scope of transient R-loops and thus ssDNA exposed for deamination by BE across the genome. This strategy increases the number of bases specified to include those by the gRNA in addition to the bases specified by a TALE or ZF domain (for example, addition of 3-finger ZF domain would specify ˜9-10 more bases than nCas9 alone).
  • To accomplish this, TALE domain arrays or ZF arrays are fused to the N- or C-termini of Cas9 proteins that are unable to bind efficiently to the target sequence specified by their gRNAs in human cells (see Table 2 for a list of proteins that can be used in these fusion proteins). Mutations to the PAM interacting domain (PID) of the Type II-A Cas9 proteins SpCas9 or SaCas9 are sufficient to prevent these proteins from functioning efficiently in human cells without a second DNA-binding domain fusion partner14,15 (see Table 2 for a list of PID mutations). Type II-C Cas9 orthologs are an evolutionarily divergent class of Cas9 enzymes that do not possess the ability to unwind double stranded DNA16. Some of these Cas9 orthologs are unable to cleave genomic sites in human cells when co-expressed with their cognate gRNAs; however, we have found that the added affinity of a 3-finger ZF fusion partner allows these Cas9 orthologs to bind and cleave genomic sites with high activity (FIG. 2). In this setup, a UGI is fused either to the opposite terminus of the ZF as the nCas9 or co-expressed with the ZF-Cas9 fusion using either a self-cleaving peptide such as a 2A element or be independently translated from an internal ribosome entry site. This strategy can also be used with TALE DNA binding domains in place of the ZFs. In any configuration, such configurations can be used to enhance BE fidelity by extending the functional DNA binding site specified by the targeting complex.
  • Bipartite Base Editor (BBE) Architecture Limits Off-Target Deamination, Enhances Product Purity & Enables Spatial Control of the Base Editing Window
  • A bipartite BE (BBE) platform, which includes a non-R-loop-forming DNA-binding domain (such as a ZF or a TALE) fused to a deaminase domain and an R-loop-forming Cas9 component (either catalytically inactive dCas9 or nicking nCas9 or a similarly inactive Cas9 ortholog) that are targeted to adjacent sequences as shown in FIG. 3, can also be used to enhance BE specificity. In this configuration, binding of the deaminase-containing protein requires adjacent binding of an R-loop-forming protein to function efficiently, since deaminases (in principle, any deaminase domain listed in Table 2, or any other enzymatic domain capable of chemically mutating DNA bases, can be considered) used for base-editing are primarily active on ssDNA, which is exposed during R-loop formation. This configuration can be used to increase specificity by effectively extending the overall number of DNA bases that need to be bound by the complex to mutate DNA, since each off-target binding of either the ZF- or TALE-deaminase or R-loop forming components on their own should have a reduced capacity to mutate DNA. Though it still includes a fully-intact deaminase enzyme, off target binding of a zinc finger-deaminase protein has a significantly reduced capacity to cause mutations compared to standard BEs since the ZF-deaminase lacks the capability to create a stable R-loop to expose ssDNA. At the same time, off-target binding of a dCas9 or nCas9 molecule has no capacity to stimulate unwanted deamination events on its own, since it lacks a deaminase domain, so it can be considered enzymatically inert and can only induce low-level off-target mutations through its ability to create single-stranded nicks in DNA or by exposing ssDNA to other nuclear factors as a by-product of R-loop formation.
  • Second, while the nCas9 (with or without UGI) component of a BBE can bind to and nick putative off-target sites in this configuration, it cannot stimulate off-target base-editing on its own since it lacks a deaminase domain. Being a highly modular system, on-target deamination can be tightly controlled by co-expression/application of various nicking or catalytically inactive Cas9 variants (see Table 1 for possible orthologs), e.g., enabling different PAM preferences. In summary, the genomic co-localization (an “AND gate”) comes from two different proteins that are independently expressed minimizing off-targeting risk. Each “half” of this bipartite base editing (BBE) system will be necessary to direct deaminase-mediated mutagenesis at a target site of interest, reducing the potential of off-target deamination and resulting mutations at nCas9 off-target sites across the genome by limiting deaminase localization to sites adjacent to nCas9-mediated R-loop formation.
  • In summary, the BBE platform offers highly optimized product purity at constant or potentially enhanced target cytosine to thymine editing efficiency with the benefit of enhanced editing window control and the prospect of reduced genome-wide Cas9-associated off-target deamination.
    • DNA Binding Domain
  • The present fusion proteins can include one, two, or more DNA binding domains such as zinc-finger nucleases, transcription activator effectors (TALEs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas RNA-guided nucleases (RGN).
  • CRISPR-Cas Nucleases
  • Although herein we refer to nCas9 and dCas9, in general, for the BBE system any R-loop forming Cas9-like enzyme that is inactive or has only nickase activity could be used, e.g., any ortholog of the Cas9 protein (including the related Cpf1 enzyme class), unless specifically indicated.
  • TABLE 1
    List of Exemplary Cas9 Orthologs
    UniProt Nickase
    Accession Mutations/Catalytic
    Ortholog Number residues
    S. pyogenes Cas9 (SpCas9) Q99ZW2 D10A, E762A, H840A,
    N854A, N863A, D986A18
    S. aureus Cas9 (SaCas9) J7RUA5 D10A and N5801819
    S. thermophilus Cas9 G3ECR1 D31A and N891A20
    (St1Cas9)
    S. pasteurianus Cas9 F5X275 D10, H599*
    (SpaCas9)
    C. jejuni Cas9 (CjCas9) Q0P897 D8A, H559A21
    F. novicida Cas9 (FnCas9) A0Q5Y3 D11, N99522
    P. lavamentivorans Cas9 A7HP89 D8, H601*
    (PlCas9)
    C. lari Cas9 (ClCas9) G1UFN3 D7, H567*
    F. novicida Cpf1 A0Q7Q2 D917, E1006, D125523
    (FnCpf1)
    M. bovoculi Cpf1 Sequence N/A**
    (MbCpf1) given
    at end
    A. sp. BV3L6 (AsCpf1) U2UMQ6 D908, 993E, Q1226,
    D126324
    L. bacterium N2006 A0A182DWE3 D832A25
    (LbCpf1)
    *predicted based on UniRule annotation on the UniProt database.
    **May be determinable based on sequence alignment with other Cpf1 orthologs

    These orthologs, and mutants and variants thereof as known in the art, can be used in any of the fusion proteins described herein. See, e.g., WO 2017/040348 (which describes variants of SaCas9 and SpCas 9 with increased specificity) and WO 2016/141224 (which describes variants of SaCas9 and SpCas9 with altered PAM specificity).
  • The Cas9 nuclease from S. pyogenes (hereafter simply Cas9) can be guided via simple base pair complementarity between 17-20 nucleotides of an engineered guide RNA (gRNA), e.g., a single guide RNA or crRNA/tracrRNA pair, and the complementary strand of a target genomic DNA sequence of interest that lies next to a protospacer adjacent motif (PAM), e.g., a PAM matching the sequence NGG or NAG (Shen et al., Cell Res (2013); Dicarlo et al., Nucleic Acids Res (2013); Jiang et al., Nat Biotechnol 31, 233-239 (2013); Jinek et al., Elife 2, e00471 (2013); Hwang et al., Nat Biotechnol 31, 227-229 (2013); Cong et al., Science 339, 819-823 (2013); Mali et al., Science 339, 823-826 (2013c); Cho et al., Nat Biotechnol 31, 230-232 (2013); Jinek et al., Science 337, 816-821 (2012)). The engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nuclease can also be used, e.g., as described in Zetsche et al., Cell 163, 759-771 (2015); Schunder et al., Int J Med Microbiol 303, 51-60 (2013); Makarova et al., Nat Rev Microbiol 13, 722-736 (2015); Fagerlund et al., Genome Biol 16, 251 (2015). Unlike SpCas9, Cpf1 requires only a single 42-nt crRNA, which has 23 nt at its 3′ end that are complementary to the protospacer of the target DNA sequence (Zetsche et al., 2015). Furthermore, whereas SpCas9 recognizes an NGG PAM sequence that is 3′ of the protospacer, AsCpf1 and LbCp1 recognize TTTN PAMs that are found 5′ of the protospacer (Id.).
  • In some embodiments, the present system utilizes a wild type or variant Cas9 protein from S. pyogenes or Staphylococcus aureus, or a wild type Cpf1 protein from Acidaminococcus sp. BV3L6 or Lachnospiraceae bacterium ND2006 either as encoded in bacteria or codon-optimized for expression in mammalian cells and/or modified in its PAM recognition specificity and/or its genome-wide specificity. A number of variants have been described; see, e.g., WO 2016/141224, PCT/US2016/049147, Kleinstiver et al., Nat Biotechnol. 2016 August; 34(8):869-74; Tsai and Joung, Nat Rev Genet. 2016 May; 17(5):300-12; Kleinstiver et al., Nature. 2016 Jan. 28; 529(7587):490-5; Shmakov et al., Mol Cell. 2015 Nov. 5; 60(3):385-97; Kleinstiver et al., Nat Biotechnol. 2015 December; 33(12):1293-1298; Dahlman et al., Nat Biotechnol. 2015 November; 33(11):1159-61; Kleinstiver et al., Nature. 2015 Jul. 23; 523(7561):481-5; Wyvekens et al., Hum Gene Ther. 2015 July; 26(7):425-31; Hwang et al., Methods Mol Biol. 2015; 1311:317-34; Osborn et al., Hum Gene Ther. 2015 February; 26(2):114-26; Konermann et al., Nature. 2015 Jan. 29; 517(7536):583-8; Fu et al., Methods Enzymol. 2014; 546:21-45; and Tsai et al., Nat Biotechnol. 2014 June; 32(6):569-76, inter alia. The guide RNA is expressed or present in the cell together with Cas9 or Cpf1. Either the guide RNA or the nuclease, or both, can be expressed transiently or stably in the cell or introduced as a purified protein or nucleic acid.
  • Table 2 shows potential Cas9 orthologs that can be used as chimeric proteins with ZFs or TALEs. PlCas9, ClCas9, and NcCas9 are unable to efficiently bind their target sites in eukaryotic cells, while CjCas9 has substantial activity at its target sites, necessitating PAM interacting domain mutations to knock down its ability to efficiently bind its site. Nickase mutation residues represents a position of the enzyme either known to be required for catalytic activity of the conserved RuvC nuclease domain or predicted to be required for this catalytic activity based on sequence alignment to CjCas9 where structural information is lacking
  • TABLE 2
    Cas9 orthologs
    Nickase
    Cas9 ortholog Enzyme class PID mutations mutation
    SpCas9 Type II-A R1333K/S, R1335K/S D10A
    SaCas9 Type II-A E782K/N968K/R1015H D10A
    PlCas9* Type II-C — D8A
    ClCas9* Type II-C — D7A
    NcCas9* Type II-C — D8A
    CjCas9 Type II-C R866K/S, T913S, S915T D8A
    *indicates proteins lacking sufficient structural information. All positional information refers to the wild-type protein sequences acquired from uniprot.org.
  • In some embodiments, the Cas9 also includes one or mutations that reduce nuclease activity of the Cas9; e.g., for SpCas9, mutations at D10A or H840A (which creates a single-strand nickase).
  • In some embodiments, the SpCas9 variants also include mutations at one of the following amino acid positions, which destroy the nuclease activity of the Cas9: D10, E762, D839, H983, or D986 and H840 or N863, e.g., D10A/D10N and H840A/H840N/H840Y, to render the nuclease portion of the protein catalytically inactive; substitutions at these positions could be alanine (as they are in Nishimasu al., Cell 156, 935-949 (2014)), or other residues, e.g., glutamine, asparagine, tyrosine, serine, or aspartate, e.g., E762Q, H983N, H983Y, D986N, N863D, N863S, or N863H (see WO 2014/152432).
  • In some embodiments, the fusion proteins include one or more Uracil glycosylase inhibitor (UGI) protein sequences; an exemplary UGI sequence is as follows: TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVM LLTSDAPEYKPWALVIQDSNGENKIKML (SEQ ID NO:7; Uniprot: P14739). Typically, the UGIs are at the C-terminal, but can also be at the N terminal, or between the components of the fusion proteins described herein. Linkers as known in the art can be used.
  • TAL Effector Repeat Arrays
  • TAL effectors of plant pathogenic bacteria in the genus Xanthomonas play important roles in disease, or trigger defense, by binding host DNA and activating effector-specific host genes. Specificity depends on an effector-variable number of imperfect, typically ˜33-35 amino acid repeats. Polymorphisms are present primarily at repeat positions 12 and 13, which are referred to herein as the repeat variable-diresidue (RVD). The RVDs of TAL effectors correspond to the nucleotides in their target sites in a direct, linear fashion, one RVD to one nucleotide, with some degeneracy and no apparent context dependence. In some embodiments, the polymorphic region that grants nucleotide specificity may be expressed as a triresidue or triplet.
  • Each DNA binding repeat can include a RVD that determines recognition of a base pair in the target DNA sequence, wherein each DNA binding repeat is responsible for recognizing one base pair in the target DNA sequence. In some embodiments, the RVD can comprise one or more of: HA for recognizing C; ND for recognizing C; HI for recognizing C; HN for recognizing G; NA for recognizing G; SN for recognizing G or A; YG for recognizing T; and NK for recognizing C and one or more of: HD for recognizing C; NG for recognizing T; NI for recognizing A; NN for recognizing G or A; NS for recognizing A or C or G or T; N* for recognizing C or T, wherein * represents a gap in the second position of the RVD; HG for recognizing T; H* for recognizing T, wherein * represents a gap in the second position of the RVD; and IG for recognizing T.
  • TALE proteins may be useful in research and biotechnology as targeted chimeric nucleases that can facilitate homologous recombination in genome engineering (e.g., to add or enhance traits useful for biofuels or biorenewables in plants). These proteins also may be useful as, for example, transcription factors, and especially for therapeutic applications requiring a very high level of specificity such as therapeutics against pathogens (e.g., viruses) as non-limiting examples.
  • Methods for generating engineered TALE arrays are known in the art, see, e.g., the fast ligation-based automatable solid-phase high-throughput (FLASH) system described in U.S. Ser. No. 61/610,212, and Reyon et al., Nature Biotechnology 30, 460-465 (2012); as well as the methods described in Bogdanove & Voytas, Science 333, 1843-1846 (2011); Bogdanove et al., Curr Opin Plant Biol 13, 394-401 (2010); Scholze & Boch, J. Curr Opin Microbiol (2011); Boch et al., Science 326, 1509-1512 (2009); Moscou & Bogdanove, Science 326, 1501 (2009); Miller et al., Nat Biotechnol 29, 143-148 (2011); Morbitzer et al., T. Proc Natl Acad Sci USA 107, 21617-21622 (2010); Morbitzer et al., Nucleic Acids Res 39, 5790-5799 (2011); Zhang et al., Nat Biotechnol 29, 149-153 (2011); Geissler et al., PLoS ONE 6, e19509 (2011); Weber et al., PLoS ONE 6, e19722 (2011); Christian et al., Genetics 186, 757-761 (2010); Li et al., Nucleic Acids Res 39, 359-372 (2011); Mahfouz et al., Proc Natl Acad Sci USA 108, 2623-2628 (2011); Mussolino et al., Nucleic Acids Res (2011); Li et al., Nucleic Acids Res 39, 6315-6325 (2011); Cermak et al., Nucleic Acids Res 39, e82 (2011); Wood et al., Science 333, 307 (2011); Hockemeye et al. Nat Biotechnol 29, 731-734 (2011); Tesson et al., Nat Biotechnol 29, 695-696 (2011); Sander et al., Nat Biotechnol 29, 697-698 (2011); Huang et al., Nat Biotechnol 29, 699-700 (2011); and Zhang et al., Nat Biotechnol 29, 149-153 (2011); all of which are incorporated herein by reference in their entirety.
  • Also suitable for use in the present methods are MegaTALs, which are a fusion of a meganuclease with a TAL effector; see, e.g., Boissel et al., Nucl. Acids Res. 42(4):2591-2601 (2014); Boissel and Scharenberg, Methods Mol Biol. 2015; 1239:171-96.
  • Zinc Fingers
  • Zinc finger proteins are DNA-binding proteins that contain one or more zinc fingers, independently folded zinc-containing mini-domains, the structure of which is well known in the art and defined in, for example, Miller et al., 1985, EMBO J., 4:1609; Berg, 1988, Proc. Natl. Acad. Sci. USA, 85:99; Lee et al., 1989, Science. 245:635; and Klug, 1993, Gene, 135:83. Crystal structures of the zinc finger protein Zif268 and its variants bound to DNA show a semi-conserved pattern of interactions, in which typically three amino acids from the alpha-helix of the zinc finger contact three adjacent base pairs or a “subsite” in the DNA (Pavletich et al., 1991, Science, 252:809; Elrod-Erickson et al., 1998, Structure, 6:451). Thus, the crystal structure of Zif268 suggested that zinc finger DNA-binding domains might function in a modular manner with a one-to-one interaction between a zinc finger and a three-base-pair “subsite” in the DNA sequence. In naturally occurring zinc finger transcription factors, multiple zinc fingers are typically linked together in a tandem array (e.g., of 3, 4, or 6 zinc fingers) to achieve sequence-specific recognition of a contiguous DNA sequence (Klug, 1993, Gene 135:83).
  • Multiple studies have shown that it is possible to artificially engineer the DNA binding characteristics of individual zinc fingers by randomizing the amino acids at the alpha-helical positions involved in DNA binding and using selection methodologies such as phage display to identify desired variants capable of binding to DNA target sites of interest (Rebar et al., 1994, Science, 263:671; Choo et al., 1994 Proc. Natl. Acad. Sci. USA, 91:11163; Jamieson et al., 1994, Biochemistry 33:5689; Wu et al., 1995 Proc. Natl. Acad. Sci. USA, 92: 344). Such recombinant zinc finger proteins can be fused to functional domains, such as transcriptional activators, transcriptional repressors, methylation domains, and nucleases to regulate gene expression, alter DNA methylation, and introduce targeted alterations into genomes of model organisms, plants, and human cells (Carroll, 2008, Gene Ther., 15:1463-68; Cathomen, 2008, Mol. Ther., 16:1200-07; Wu et al., 2007, Cell. Mol. Life Sci., 64:2933-44).
  • One existing method for engineering zinc finger arrays, known as “modular assembly,” advocates the simple joining together of pre-selected zinc finger modules into arrays (Segal et al., 2003, Biochemistry, 42:2137-48; Beerli et al., 2002, Nat. Biotechnol., 20:135-141; Mandell et al., 2006, Nucleic Acids Res., 34:W516-523; Carroll et al., 2006, Nat. Protoc. 1:1329-41; Liu et al., 2002, J. Biol. Chem., 277:3850-56; Bae et al., 2003, Nat. Biotechnol., 21:275-280; Wright et al., 2006, Nat. Protoc., 1:1637-52). Although straightforward enough to be practiced by any researcher, recent reports have demonstrated a high failure rate for this method, particularly in the context of zinc finger nucleases (Ramirez et al., 2008, Nat. Methods, 5:374-375; Kim et al., 2009, Genome Res. 19:1279-88), a limitation that typically necessitates the construction and cell-based testing of very large numbers of zinc finger proteins for any given target gene (Kim et al., 2009, Genome Res. 19:1279-88).
  • Combinatorial selection-based methods that identify zinc finger arrays from randomized libraries have been shown to have higher success rates than modular assembly (Maeder et al., 2008, Mol. Cell, 31:294-301; Joung et al., 2010, Nat. Methods, 7:91-92; Isalan et al., 2001, Nat. Biotechnol., 19:656-660). In preferred embodiments, the zinc finger arrays are described in, or are generated as described in, WO 2011/017293 and WO 2004/099366. Additional suitable zinc finger DBDs are described in U.S. Pat. Nos. 6,511,808, 6,013,453, 6,007,988, and 6,503,717 and U.S. patent application 2002/0160940.
    • Bipartite Base Editors
  • In some embodiments, the base editor is a fusion of a DNA-binding domain to a deaminase, or an active portion thereof, that modifies cytosine DNA bases, e.g., a cytidine deaminase from the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) family of deaminases, including APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4 (see, e.g., Yang et al., J Genet Genomics. 2017 Sep. 20; 44(9):423-437); activation-induced cytidine deaminase (AID), e.g., activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT). The following Table 2 provides exemplary sequences; other sequences can also be used.
  • TABLE 2
    Gen Bank Accession Nos.
    Deaminase Nucleic Acid Amino Acid
    hAID/AICDA NM_020661.3 isoform 1 NP_065712.1 variant 1
    NM_020661.3 isoform 2 NP_065712.1 variant 2
    rat APOBEC1 NM_012907.2 NP_037039.1
    hAPOBEC1 NM_001644.4 isoform a NP_001635.2 variant 1
    NM_005889.3 isoform b NP_005880.2 variant 3
    hAPOBEC2 NM_006789.3 NP_006780.1
    hAPOBEC3A NM_145699.3 isoform a NP_663745.1 variant 1
    NM_001270406.1 NP_001257335.1
    isoform b variant 2
    hAPOBEC3B NM_004900.4 isoform a NP_004891.4 variant 1
    NM_001270411.1 NP_001257340.1
    isoform b variant 2
    hAPOBEC3C NM_014508.2 NP_055323.2
    hAPOBEC3D NM_152426.3 NP_689639.2
    APOBEC3F NM_145298.5 isoform a NP_660341.2 variant 1
    NM_001006666.1 NP_001006667.1
    isoform b variant 2
    APOBEC3G NM_021822.3 (isoform a) NP_068594.1 (variant 1)
    APOBEC3H NM_001166003.2 NP_001159475.2
    (variant SV-200)
    APOBEC4 NM_203454.2 NP_982279.1
    CDA1* NM_127515.4 NP_179547.1
    *from Saccharomyces cerevisiae S288C
    • Variants
  • In some embodiments, the components of the fusion proteins are at least 80%, e.g., at least 85%, 90%, 95%, 97%, or 99% identical to the amino acid sequence of a exemplary sequence (e.g., as provided herein), e.g., have differences at up to 5%, 10%, 15%, or 20% of the residues of the exemplary sequence replaced, e.g., with conservative mutations, in addition to the mutations described herein. In preferred embodiments, the variant retains desired activity of the parent, e.g., in the case of a Cas9 variant or fragment, nickase activity or no nuclease activity, and/or the ability to interact with a guide RNA and/or target DNA, or deaminase activity in the case of a deaminase variant or active portion thereof.
  • To determine the percent identity of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%. The nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein nucleic acid “identity” is equivalent to nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. Percent identity between two polypeptides or nucleic acid sequences is determined in various ways that are within the skill in the art, for instance, using publicly available computer software such as Smith Waterman Alignment (Smith, T. F. and M. S. Waterman (1981) J Mol Biol 147:195-7); “BestFit” (Smith and Waterman, Advances in Applied Mathematics, 482-489 (1981)) as incorporated into GeneMatcher Plus™, Schwarz and Dayhof (1979) Atlas of Protein Sequence and Structure, Dayhof, M. O., Ed, pp 353-358; BLAST program (Basic Local Alignment Search Tool; (Altschul, S. F., W. Gish, et al. (1990) J Mol Biol 215: 403-10), BLAST-2, BLAST-P, BLAST-N, BLAST-X, WU-BLAST-2, ALIGN, ALIGN-2, CLUSTAL, or Megalign (DNASTAR) software. In addition, those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the length of the sequences being compared. In general, for proteins or nucleic acids, the length of comparison can be any length, up to and including full length (e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%). For purposes of the present compositions and methods, at least 80% of the full length of the sequence is aligned.
  • For purposes of the present disclosure, the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
  • Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
  • Also provided herein are isolated nucleic acids encoding the bipartite deaminase fusion proteins, vectors comprising the isolated nucleic acids, optionally operably linked to one or more regulatory domains for expressing the variant proteins, and host cells, e.g., mammalian host cells, comprising the nucleic acids, and optionally expressing the variant proteins. In some embodiments, the host cells are stem cells, e.g., hematopoietic stem cells.
  • The bipartite deaminase fusion proteins described herein can be used for altering the genome of a cell. The methods generally include expressing or contacting the fusion proteins in the cells; in versions using one or two Cas9s, the methods include using a guide RNA having a region complementary to a selected portion of the genome of the cell. Methods for selectively altering the genome of a cell are known in the art, see, e.g., U.S. Pat. No. 8,993,233; US 20140186958; U.S. Pat. No. 9,023,649; WO/2014/099744; WO 2014/089290; WO2014/144592; WO144288; WO2014/204578; WO2014/152432; WO2115/099850; U.S. Pat. No. 8,697,359; US20160024529; US20160024524; US20160024523; US20160024510; US20160017366; US20160017301; US20150376652; US20150356239; US20150315576; US20150291965; US20150252358; US20150247150; US20150232883; US20150232882; US20150203872; US20150191744; US20150184139; US20150176064; US20150167000; US20150166969; US20150159175; US20150159174; US20150093473; US20150079681; US20150067922; US20150056629; US20150044772; US20150024500; US20150024499; US20150020223; US20140356867; US20140295557; US20140273235; US20140273226; US20140273037; US20140189896; US20140113376; US20140093941; US20130330778; US20130288251; US20120088676; US20110300538; US20110236530; US20110217739; US20110002889; US20100076057; US20110189776; US20110223638; US20130130248; US20150050699; US20150071899; US20150050699; US20150045546; US20150031134; US20150024500; US20140377868; US20140357530; US20140349400; US20140335620; US20140335063; US20140315985; US20140310830; US20140310828; US20140309487; US20140304853; US20140298547; US20140295556; US20140294773; US20140287938; US20140273234; US20140273232; US20140273231; US20140273230; US20140271987; US20140256046; US20140248702; US20140242702; US20140242700; US20140242699; US20140242664; US20140234972; US20140227787; US20140212869; US20140201857; US20140199767; US20140189896; US20140186958; US20140186919; US20140186843; US20140179770; US20140179006; US20140170753; WO/2008/108989; WO/2010/054108; WO/2012/164565; WO/2013/098244; WO/2013/176772; US 20150071899; Makarova et al., “Evolution and classification of the CRISPR-Cas systems” 9(6) Nature Reviews Microbiology 467-477 (1-23) (June 2011); Wiedenheft et al., “RNA-guided genetic silencing systems in bacteria and archaea” 482 Nature 331-338 (Feb. 16, 2012); Gasiunas et al., “Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria” 109(39) Proceedings of the National Academy of Sciences USA E2579-E2586 (Sep. 4, 2012); Jinek et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity” 337 Science 816-821 (Aug. 17, 2012); Carroll, “A CRISPR Approach to Gene Targeting” 20(9) Molecular Therapy 1658-1660 (September 2012); U.S. Appl. No. 61/652,086, filed May 25, 2012; Al-Attar et al., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs): The Hallmark of an Ingenious Antiviral Defense Mechanism in Prokaryotes, Biol Chem. (2011) vol. 392, Issue 4, pp. 277-289; Hale et al., Essential Features and Rational Design of CRISPR RNAs That Function With the Cas RAMP Module Complex to Cleave RNAs, Molecular Cell, (2012) vol. 45, Issue 3, 292-302.
  • In some embodiments, the fusion proteins include a linker between the DNA binding domain (e.g., ZFN, TALE, or nCas9) and the BE domains. Linkers that can be used in these fusion proteins (or between fusion proteins in a concatenated structure) can include any sequence that does not interfere with the function of the fusion proteins. In preferred embodiments, the linkers are short, e.g., 2-20 amino acids, and are typically flexible (i.e., comprising amino acids with a high degree of freedom such as glycine, alanine, and serine). In some embodiments, the linker comprises one or more units consisting of GGGS (SEQ ID NO:8) or GGGGS (SEQ ID NO:9), e.g., two, three, four, or more repeats of the GGGS (SEQ ID NO:8) or GGGGS (SEQ ID NO:9) unit. Other linker sequences can also be used.
  • In some embodiments, the fusion protein includes a cell-penetrating peptide sequence that facilitates delivery to the intracellular space, e.g., HIV-derived TAT peptide, penetratins, transportans, or hCT derived cell-penetrating peptides, see, e.g., Caron et al., (2001) Mol Ther. 3(3):310-8; Langel, Cell-Penetrating Peptides: Processes and Applications (CRC Press, Boca Raton Fla. 2002); El-Andaloussi et al., (2005) Curr Pharm Des. 11(28):3597-611; and Deshayes et al., (2005) Cell Mol Life Sci. 62(16):1839-49.
  • Cell penetrating peptides (CPPs) are short peptides that facilitate the movement of a wide range of biomolecules across the cell membrane into the cytoplasm or other organelles, e.g. the mitochondria and the nucleus. Examples of molecules that can be delivered by CPPs include therapeutic drugs, plasmid DNA, oligonucleotides, siRNA, peptide-nucleic acid (PNA), proteins, peptides, nanoparticles, and liposomes. CPPs are generally 30 amino acids or less, are derived from naturally or non-naturally occurring protein or chimeric sequences, and contain either a high relative abundance of positively charged amino acids, e.g. lysine or arginine, or an alternating pattern of polar and non-polar amino acids. CPPs that are commonly used in the art include Tat (Frankel et al., (1988) Cell. 55:1189-1193, Vives et al., (1997) J. Biol. Chem. 272:16010-16017), penetratin (Derossi et al., (1994) J. Biol. Chem. 269:10444-10450), polyarginine peptide sequences (Wender et al., (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008, Futaki et al., (2001) J. Biol. Chem. 276:5836-5840), and transportan (Pooga et al., (1998) Nat. Biotechnol. 16:857-861).
  • CPPs can be linked with their cargo through covalent or non-covalent strategies. Methods for covalently joining a CPP and its cargo are known in the art, e.g. chemical cross-linking (Stetsenko et al., (2000) J. Org. Chem. 65:4900-4909, Gait et al. (2003) Cell. Mol. Life. Sci. 60:844-853) or cloning a fusion protein (Nagahara et al., (1998) Nat. Med. 4:1449-1453). Non-covalent coupling between the cargo and short amphipathic CPPs comprising polar and non-polar domains is established through electrostatic and hydrophobic interactions.
  • CPPs have been utilized in the art to deliver potentially therapeutic biomolecules into cells. Examples include cyclosporine linked to polyarginine for immunosuppression (Rothbard et al., (2000) Nature Medicine 6(11): 1253-1257), siRNA against cyclin B1 linked to a CPP called MPG for inhibiting tumorigenesis (Crombez et al., (2007) Biochem Soc. Trans. 35:44-46), tumor suppressor p53 peptides linked to CPPs to reduce cancer cell growth (Takenobu et al., (2002) Mol. Cancer Ther. 1(12):1043-1049, Snyder et al., (2004) PLoS Biol. 2:E36), and dominant negative forms of Ras or phosphoinositol 3 kinase (PI3K) fused to Tat to treat asthma (Myou et al., (2003) J. Immunol. 171:4399-4405).
  • CPPs have been utilized in the art to transport contrast agents into cells for imaging and biosensing applications. For example, green fluorescent protein (GFP) attached to Tat has been used to label cancer cells (Shokolenko et al., (2005) DNA Repair 4(4):511-518). Tat conjugated to quantum dots have been used to successfully cross the blood-brain barrier for visualization of the rat brain (Santra et al., (2005) Chem. Commun. 3144-3146). CPPs have also been combined with magnetic resonance imaging techniques for cell imaging (Liu et al., (2006) Biochem. and Biophys. Res. Comm. 347(1):133-140). See also Ramsey and Flynn, Pharmacol Ther. 2015 Jul. 22. pii: S0163-7258(15)00141-2.
  • Alternatively or in addition, the fusion proteins can include a nuclear localization sequence, e.g., SV40 large T antigen NLS (PKKKRRV (SEQ ID NO: 10)) and nucleoplasmin NLS (KRPAATKKAGQAKKKK (SEQ ID NO: 11)). Other NLSs are known in the art; see, e.g., Cokol et al., EMBO Rep. 2000 Nov. 15; 1(5): 411-415; Freitas and Cunha, Curr Genomics. 2009 December; 10(8): 550-557.
  • In some embodiments, the fusion proteins include a moiety that has a high affinity for a ligand, for example GST, FLAG or hexahistidine sequences. Such affinity tags can facilitate the purification of recombinant fusion proteins.
  • For methods in which the fusion proteins are delivered to cells, the proteins can be produced using any method known in the art, e.g., by in vitro translation, or expression in a suitable host cell from nucleic acid encoding the fusion protein; a number of methods are known in the art for producing proteins. For example, the proteins can be produced in and purified from yeast, E. coli, insect cell lines, plants, transgenic animals, or cultured mammalian cells; see, e.g., Palomares et al., “Production of Recombinant Proteins: Challenges and Solutions,” Methods Mol Biol. 2004; 267:15-52. In addition, the fusion proteins can be linked to a moiety that facilitates transfer into a cell, e.g., a lipid nanoparticle, optionally with a linker that is cleaved once the protein is inside the cell. See, e.g., LaFountaine et al., Int J Pharm. 2015 Aug. 13; 494(1):180-194.
  • Expression Systems
  • To use the fusion proteins described herein, it may be desirable to express them from a nucleic acid that encodes them. This can be performed in a variety of ways. For example, the nucleic acid encoding the fusion can be cloned into an intermediate vector for transformation into prokaryotic or eukaryotic cells for replication and/or expression. Intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors, or insect vectors, for storage or manipulation of the nucleic acid encoding the fusion for production of the fusion protein. The nucleic acid encoding the fusion protein can also be cloned into an expression vector, for administration to a plant cell, animal cell, preferably a mammalian cell or a human cell, fungal cell, bacterial cell, or protozoan cell.
  • To obtain expression, a sequence encoding a fusion protein is typically subcloned into an expression vector that contains a promoter to direct transcription. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual (3d ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 2010). Bacterial expression systems for expressing the engineered protein are available in, e.g., E. coli, Bacillus sp., and Salmonella (Palva et al., 1983, Gene 22:229-235). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.
  • The promoter used to direct expression of a nucleic acid depends on the particular application. For example, a strong constitutive promoter is typically used for expression and purification of fusion proteins. In contrast, when the fusion protein is to be administered in vivo for gene regulation, either a constitutive or an inducible promoter can be used, depending on the particular use of the fusion protein. In addition, a preferred promoter for administration of the fusion protein can be a weak promoter, such as HSV TK or a promoter having similar activity. The promoter can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Gal4 response elements, lac repressor response element, and small molecule control systems such as tetracycline-regulated systems and the RU-486 system (see, e.g., Gossen & Bujard, 1992, Proc. Natl. Acad. Sci. USA, 89:5547; Oligino et al., 1998, Gene Ther., 5:491-496; Wang et al., 1997, Gene Ther., 4:432-441; Neering et al., 1996, Blood, 88:1147-55; and Rendahl et al., 1998, Nat. Biotechnol., 16:757-761).
  • In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic. A typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence encoding the fusion protein, and any signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination. Additional elements of the cassette may include, e.g., enhancers, and heterologous spliced intronic signals.
  • The particular expression vector used to transport the genetic information into the cell is selected with regard to the intended use of the fusion protein, e.g., expression in plants, animals, bacteria, fungus, protozoa, etc. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and commercially available tag-fusion expression systems such as GST and LacZ.
  • Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG pAV009/A+, pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
  • The vectors for expressing the fusion protein can include RNA Pol III promoters to drive expression of the guide RNAs, e.g., the HI, U6 or 7SK promoters. These human promoters allow for expression of fusion protein in mammalian cells following plasmid transfection.
  • Some expression systems have markers for selection of stably transfected cell lines such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. High yield expression systems are also suitable, such as using a baculovirus vector in insect cells, with the gRNA encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.
  • The elements that are typically included in expression vectors also include a replicon that functions in E. coli, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of recombinant sequences.
  • Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of protein, which are then purified using standard techniques (see, e.g., Colley et al., 1989, J. Biol. Chem., 264:17619-22; Guide to Protein Purification, in Methods in Enzymology, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (see, e.g., Morrison, 1977, J. Bacteriol. 132:349-351; Clark-Curtiss & Curtiss, Methods in Enzymology 101:347-362 (Wu et al., eds, 1983).
  • Any of the known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, nucleofection, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both episomal and integrative, and any of the other well-known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the fusion protein.
  • Alternatively, the methods can include delivering the fusion protein and guide RNA together, e.g., as a complex. For example, the fusion protein and gRNA can be can be overexpressed in a host cell and purified, then complexed with the guide RNA (e.g., in a test tube) to form a ribonucleoprotein (RNP), and delivered to cells. In some embodiments, the fusion protein can be expressed in and purified from bacteria through the use of bacterial expression plasmids. For example, His-tagged fusion protein can be expressed in bacterial cells and then purified using nickel affinity chromatography. The use of RNPs circumvents the necessity of delivering plasmid DNAs encoding the nuclease or the guide, or encoding the nuclease as an mRNA. RNP delivery may also improve specificity, presumably because the half-life of the RNP is shorter and there's no persistent expression of the nuclease and guide (as you'd get from a plasmid). The RNPs can be delivered to the cells in vivo or in vitro, e.g., using lipid-mediated transfection or electroporation. See, e.g., Liang et al. “Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.” Journal of biotechnology 208 (2015): 44-53; Zuris, John A., et al. “Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.” Nature biotechnology 33.1 (2015): 73-80; Kim et al. “Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.” Genome research 24.6 (2014): 1012-1019.
  • The present invention also includes the vectors and cells comprising the vectors, as well as kits comprising the proteins and nucleic acids described herein, e.g., for use in a method described herein.
    • Examples
  • The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
  • Materials and Methods
  • The following materials and methods were used in the examples herein.
  • Molecular Cloning
  • Expression plasmids were constructed by selectively amplifying desired DNA sequences using the PCR method such that they had significant overlapping ends and using isothermal assembly (or “Gibson Assembly”, NEB) to assemble them in the desired order in a pCAG expression vector. PCR was conducted using Q5 or Phusion polymerases (NEB). Cas9 gRNAs were cloned using the pUC 19-based entry vector BPK 1520 (via BsmBI cassette) under control of a U6 promoter.
  • Guide RNAs and Zinc Finger Target Sites
  • The following EGFP targeting zinc fingers were used:
  • ZF 11-1 (223L), target site
    (SEQ ID NO: 12)
    gGTCGGGGTAg
    ZF 13-6 (292L), target site
    (SEQ ID NO: 13)
    aGAAGATGGTg
    Cas9 guide RNA2 protospacer (PAM):
    (SEQ ID NO: 14)
    AGCACTGCACGCCGTAGGTC(AGG)
    Cas9 guide RNA4 protospacer (PAM):
    (SEQ ID NO: 15)
    CATGCCCGAAGGCTACGTCC(AGG)
    Cas9 guide RNA5 protospacer (PAM):
    (SEQ ID NO: 16)
    CTGGACGTAGCCTTCGGGCA(TGG)
  • Cell Culture and Transfections
  • For the BBE experiments, a HEK293 cell line in which an integrated EGFP reporter gene has been integrated (unpublished) was grown in culture using media consisting of Advanced Dulbeccos Modified Medium (Gibco) supplemented with 10% FBS (Gibco), 1% 10,000 U/ml penicillin-streptomycin solution (Gibco), and 1% Glutamax (Gibco). Cells were passaged every 3-4 days to maintain an actively growing population and avoid anoxic conditions. Transfections containing 800 nanogram of transfection quality DNA (Qiagen Maxi- or Miniprep) encoding desired proteins/gRNAs were conducted by seeding 1×105 cells in 24-well TC-treated plates and using TransIT-293 reagent according to manufacturer's protocol (Mirus Bio). gDNA was harvested 3 days post-transfection using the DNAdvance kit (Agencourt). U2OS.EGFP cells containing a single stably integrated copy of the EGFP-PEST reporter gene and HEK293T cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM GlutaMax, penicillin and streptomycin at 37° C. with 5% C02.
  • The media for U2OS.EGFP cells was supplemented with 400 μg ml−1 Geneticin. Cell line identity was validated by STR profiling (ATCC), and cells were tested regularly for mycoplasma contamination. U2OS.EGFP cells were transfected with 750 ng of plasmid expressing BE and 250 ng of plasmid expressing gRNA according to the manufacturer's recommendations using the DN-100 program and SE cell line kit on a Lonza 4-D Nucleofector. Disruption of the EGFP gene was evaluated using flow cytometry 48 hours post-transfection.
  • High-Throughput Amplicon Sequencing
  • Target site genomic DNA was amplified using gene-specific DNA primers flanking desired target sequence. Illumina TruSeq adapters were added to the ends of the amplicons either by PCR or NEBNext Ultra II kit (NEB) and molecularly indexed with NEBNext Dual Index Primers (NEB). Samples were combined into libraries and sequenced on the Illumina MiSeq machine using the MiSeq Reagent Micro Kit v2 (Illumina). Sequencing results were analyzed using a batch version of the software CRISPResso (crispresso.rocks).
  • Relevant Protein Sequences
  • N-nCas9(D10A)-SGGS linker-UGI-SV40NLS-C
    (SEQ ID NO: 17)
    MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICY
    LQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI
    KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIA
    LSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKR
    YDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
    DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGA
    SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED
    YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVM
    KQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAG
    SPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEK
    LYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKL
    ITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF
    YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLA
    NGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGF
    DSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLA
    SAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNK
    HRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSD
    IIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGG
    SPKKKRKV
    N-hAPOBEC3A-8AA linker-ZF-LRGS linker-UGI-SGGSlinker-SV40NLS-C
    (SEQ ID NO: 18)
    MEASPASGPRHLMDPHIFTSNFNNGIGREIKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVP
    SLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHC
    WDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGGGLGSTSRPGERPFQCRICMRNFSXXXXLXXHTRTHTGEKP
    FQCRICMRNFSXXXXLXXHLRTHTGEKPFQCRICMRNFSXXXXLXXHLKTHLRGSTNLSDIIEKETGKQLVIQESILMLPE
    EVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV
    N-rAPOBEC1-XTEN-8AA linker-ZF-LRGS linker-UGI-SGGS linker-SV40NLS-C
    (SEQ ID NO: 19)
    MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTR
    CSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPS
    NEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATP
    ESSGGGLGSTSRPGERPFQCRICMRNFSXXXXLXXHTRTHTGEKPFQCRICMRNFSXXXXLXXHLRTHTGEKPFQCRICMF
    SXXXXLXXHLKTHLRGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEY
    KPWALVIQDSNGENKIKMLSGGSPKKKRKV
    S. aureus Cas9
    (SEQ ID NO: 20)
    MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHS
    ELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDG
    EVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEE
    LRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFT
    NLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILD
    ELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKD
    AQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDN
    SFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVD
    TRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVME
    NQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYD
    KDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHL
    DITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLI
    KINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG
    C. jejuni Cas9
    (SEQ ID NO: 21)
    MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARRKARLNHLKHLIANEFKLNYE
    DYQSFDESLAKAYKGSLISPYELRFRALNELLSKQDFARVILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSV
    GEYLYKEYFQKFKENSKEFTNVRNKKESYERCIAQSFLKDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALKDFSHLV
    GNCSFFTDEKRAPKNSPLAFMFVALTRIINLLNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYEFKGE
    KGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNISFKALKLVT
    PLMLEGKKYDEACNELNLKVAINEDKKDFLPAFNETYYKDEVTNPVVLRAIKEYRKVLNALLKKYGKVHKINIELAREVGK
    NHSQRAKIEKEQNENYKAKKDAELECEKLGLKINSKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHIYPYSRSF
    DDSYMNKVLVFTKQNQEKLNQTPFEAFGNDSAKWQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVL
    NYTKDYLDFLPLSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVIIAYANNSIVKAFSDFK
    KEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEEFYQSYGGKEGVLK
    ALELGKIRKVNGKIVKNGDMFRVDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSKKGEIKDWILMDENYEFCFSLYKD
    SLILIQTKDMQEPEFVYYNAFTSSTVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVT
    KAEFRQREDFKK
    P. lavamentivorans Cas9
    (SEQ ID NO: 22)
    MERIFGFDIGTTSIGFSVIDYSSTQSAGNIQRLGVRIFPEARDPDGTPLNQQRRQKRMMRRQLRRRRIRRKALNETLHEAG
    FLPAYGSADWPVVMADEPYELRRRGLEEGLSAYEFGRAIYHLAQHRHFKGRELEESDTPDPDVDDEKEAANERAATLKALK
    NEQTTLGAWLARRPPSDRKRGIHAHRNVVAEEFERLWEVQSKFHPALKSEEMRARISDTIFAQRPVFWRKNTLGECRFMPG
    EPLCPKGSWLSQQRRMLEKLNNLAIAGGNARPLDAEERDAILSKLQQQASMSWPGVRSALKALYKQRGEPGAEKSLKFNLE
    LGGESKLLGNALEAKLADMFGPDWPAHPRKQEIRHAVHERLWAADYGETPDKKRVIILSEKDRKAHREAAANSFVADFGIT
    GEQAAQLQALKLPTGWEPYSIPALNLFLAELEKGERFGALVNGPDWEGWRRTNFPHRNQPTGEILDKLPSPASKEERERIS
    QLRNPTVVRTQNELRKVVNNLIGLYGKPDRIRIEVGRDVGKSKREREEIQSGIRRNEKQRKKATEDLIKNGIANPSRDDVE
    KWILWKEGQERCPYTGDQIGFNALFREGRYEVEHIWPRSRSFDNSPRNKTLCRKDVNIEKGNRMPFEAFGHDEDRWSAIQI
    RLQGMVSAKGGTGMSPGKVKRFLAKTMPEDFAARQLNDTRYAAKQILAQLKRLWPDMGPEAPVKVEAVTGQVTAQLRKLWT
    LNNILADDGEKTRADHRHHAIDALTVACTHPGMTNKLSRYWQLRDDPRAEKPALTPPWDTIRADAEKAVSEIVVSHRVRKK
    VSGPLHKETTYGDTGTDIKTKSGTYRQFVTRKKIESLSKGELDEIRDPRIKEIVAAHVAGRGGDPKKAFPPYPCVSPGGPE
    IRKVRLTSKQQLNLMAQTGNGYADLGSNHHIAIYRLPDGKADFEIVSLFDASRRLAQRNPIVQRTRADGASFVMSLAAGEA
    IMIPEGSKKGIWIVQGVWASGQVVLERDTDADHSTTTRPMPNPILKDDAKKVSIDPIGRVRPSND
    N. cinerea Cas9
    (SEQ ID NO: 23)
    MAAFKPNPMNYILGLDIGIASVGWAIVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAAARRLARSVRRLTRRRAHRLLR
    ARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGV
    ADNTHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFNRKDLQAELNLLFEKQKEFGNPHVSDGLKEGIETLLMTQR
    PALSGDAVQKMLGHCTFEPTEPKAAKNTYTAERFVWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLL
    DLDDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRVQP
    EILEALLKHISFDKFVQISLKALRRIVPLMEQGNRYDEACTEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARK
    VINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKSAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCL
    YSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLALGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSK
    KQRILLQKFDEDGFKERNLNDTRYINRFLCQFVADHMLLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVV
    VACSTIAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKAHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLL
    AEKLSSRPEAVHKYVTPLFISRAPNRKMSGQGHMETVKSAKRLDEGISVLRVPLTQLKLKDLEKMVNREREPKLYEALKAR
    LEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVHNHNGIADNATIVRVDVFEKGGKYYLVPIYSWQVAKG
    ILPDRAVVQGKDEEDWTVMDDSFEFKFVLYANDLIKLTAKKNEFLGYFVSLNRATGAIDIRTHDTDSTKGKNGIFQSVGVK
    TALSFQKYQIDELGKEIRPCRLKKRPPVR
    hAID
    (SEQ ID NO: 24)
    MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWF
    TSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAW
    EGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL
    hAIDv solubility variant lacking N-terminal RNA-binding region
    (SEQ ID NO: 25)
    MDPHIFTSNFNNGIGRHKTYLCYEVERLDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYD
    CARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSV
    RLSRQLRRILLPLYEVDDLRDAFRTLGL
    hAIDv solubility variant lacking N-terminal RNA-binding region and the
    C-terminal poorly structured region
    (SEQ ID NO: 26)
    MDPHIFTSNFNNGIGRHKTYLCYEVERLDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYD
    CARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSV
    RLSRQLRRILLPL
    rAPOBEC1
    (SEQ ID NO: 27)
    MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTR
    CSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPS
    NEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK
    mAPOBEC3
    (SEQ ID NO: 28)
    MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFH
    DKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFK
    KCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPL
    KGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSL
    WQSGILVDVMDLPQFTDCWTNFVNPKRPFRPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMSN
    mAPOBEC3 catalytic domain
    (SEQ ID NO: 29)
    MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFH
    DKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFK
    KCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRR
    hAPOBEC3A
    (SEQ ID NO: 30)
    MEASPASGPRHLMDPHIFTSNFNNGIGREIKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVP
    SLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHC
    WDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGN
    hAPOBEC3G
    (SEQ ID NO: 31)
    MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSELKYHPEMRFFHWFSKWRKLH
    RDQEYEVTWYISWSPCTKCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWS
    KFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLC
    NQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEG
    LRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN
    hAPOBEC3G catalytic domain
    (SEQ ID NO: 32)
    PPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRV
    TCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQP
    WDGLDEHSQDLSGRLRAILQNQEN
    hAPOBEC3H
    (SEQ ID NO: 33)
    MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGYFENKKKCHAEICFINEIKSMGLDETQCYQVTCYLT
    WSPCSSCAWELVDFIKAHDHLNLGIFASRLYYHWCKPQQKGLRLLCGSQVPVEVMGFPKFADCWENFVDHEKPLSFNPYKM
    LEELDKNSRAIKRRLERIKIPGVRAQGRYMDILCDAEV
    hAPOBEC3F
    (SEQ ID NO: 34)
    MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQVYSQPEHHAEMCFLSWFCGNQLPA
    YKCFQITWFVSWTPCPDCVAKLAEFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYS
    EGQPFMPWYKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVD
    PETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQE
    GASVEIMGYKDFKYCWENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE
    hAPOBEC3F catalytic domain
    (SEQ ID NO: 35)
    KEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSP
    NTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYN
    DDEPFKPWKGLKYNFLFLDSKLQEILE
    C. lari Cas9
    (SEQ ID NO: 36)
    MRILGFDIGINSIGWAFVENDELKDCGVRIFTKAENPKNKESLALPRRNARSSRRRLKRRKARLIAIKRILAKELKLNYKD
    YVAADGELPKAYEGSLASVYELRYKALTQNLETKDLARVILHIAKHRGYMNKNEKKSNDAKKGKILSALKNNALKLENYQS
    VGEYFYKEFFQKYKKNTKNFIKIRNTKDNYNNCVLSSDLEKELKLILEKQKEFGYNYSEDFINEILKVAFFQRPLKDFSHL
    VGACTFFEEEKRACKNSYSAWEFVALTKIINEIKSLEKISGEIVPTQTINEVLNLILDKGSITYKKFRSCINLHESISFKS
    LKYDKENAENAKLIDFRKLVEFKKALGVHSLSRQELDQISTHITLIKDNVKLKTVLEKYNLSNEQINNLLEIEFNDYINLS
    FKALGMILPLMREGKRYDEACEIANLKPKTVDEKKDFLPAFCDSIFAHELSNPVVNRAISEYRKVLNALLKKYGKVHKIHL
    ELARDVGLSKKAREKIEKEQKENQAVNAWALKECENIGLKASAKNILKLKLWKEQKEICIYSGNKISIEHLKDEKALEVDH
    IYPYSRSFDDSFINKVLVFTKENQEKLNKTPFEAFGKNIEKWSKIQTLAQNLPYKKKNKILDENFKDKQQEDFISRNLNDT
    RYIATLIAKYTKEYLNFLLLSENENANLKSGEKGSKIHVQTISGMLTSVLRHTWGFDKKDRNNHLHHALDAIIVAYSTNSI
    IKAFSDFRKNQELLKARFYAKELTSDNYKHQVKFFEPFKSFREKILSKIDEIFVSKPPRKRARRALHKDTFHSENKIIDKC
    SYNSKEGLQIALSCGRVRKIGTKYVENDTIVRVDIFKKQNKFYAIPIYAMDFALGILPNKIVITGKDKNNNPKQWQTIDES
    YEFCFSLYKNDLILLQKKNMQEPEFAYYNDFSISTSSICVEKHDNKFENLTSNQKLLFSNAKEGSVKVESLGIQNLKVFEK
    YIITPLGDKIKADFQPRENISLKTSKKYGLR
    • Example 1
  • We generated BBEs consisting of either a rAPOBEC1(WT)-ZF or hAPOBEC3A(WT)-ZF fusion and an nCas9-Uracil DNA Glycosylase inhibitor (UGI) targeted to adjacent sequences. An nCas9-UGI architecture mimics the standard BE3 architecture that is known to be an important part of a functional BE protein. As there is evidence for the use of a second UGI to enhance product purity we fused a UGI to both the ZF (via LRGS linker) as well as the nCas9 (same linker as in conventional BE3) C-terminus17.
  • In addition, the physical separation of the deaminase domain from nCas9 and fusion of UGI to both components of the bipartite base editor seemed to yield lower synergistic on-target side effects of conventional base editors such as insertions/deletion (indels) or unwanted substitutions (cytosine to purine, e.g., C-to-G or C-to-A), commonly referred to as “product impurities.” This property may arise for a stronger inhibition of the UDG enzyme by UGI, which is known to aid in product purity of BEs.
  • When targeted to adjacent sites 6-8 basepairs apart from each other on an integrated EGFP reporter gene in HEK293 cells, both rAPOBEC1 and hAPOBEC3A BBEs are able to stimulate efficient base-editing at rates similar to or greater than monomeric BE counterparts (of the form deaminase-nCas9-UGI). (FIGS. 4-6). This effect is consistent regardless of the orientation of the two components with respect to each other and works using multiple different ZFs or gRNAs. When the ZF-deaminase fusion was targeted upstream (toward the 5′ end) of the nCas9 site, the BBE mutated cytosines in a similar “editing window” as those described for conventional BEs and with a similar distribution (FIGS. 4 and 5). When the ZF-deaminase is positioned 8 basepairs downstream of the nCas9 site, the BBE has a much broader editing window that shifts towards the 3′ end of the gRNA target site, suggesting a possible control of the editing window by programmed proximity of the deaminase-containing bipartite “half”. This editing window flexibility adds spatial control to the bipartite base editing circuitry (FIG. 6). It is conceivable or even likely that as-yet untested BBE spatial orientations and spacings will uncover more interesting and useful properties of BBEs. ZFs used in these experiments were originally constructed using the OPEN method and subsequently described as highly active DNA-binding proteins. Expectedly, using a dual UGI approach reduces the amount of target site cytosine-to-guanine and cytosine-to-adenine editing (FIGS. 7A & 7B).8 Most importantly though, and not necessarily only attributable to the second UGI, we saw a substantial reduction in indel formation using BBEs (FIGS. 7C & 7D), thus indicating that BBEs may represent a base editing methodology with significantly fewer product impurities and improved off-targeting properties.
    • REFERENCES
    • 1. Komor A C, Kim B, Packer M S, Zuris J A, Liu D R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533. doi:10.1038/naturel 7946.
    • 2. Gaudelli N M, Komor A C, Rees H A, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017:1-27. doi: 10.1038/nature24644.
    • 3. Yang L, Briggs A W, Chew W L, et al. Engineering and optimising deaminase fusions for genome editing. Nat Commun. 2016; 7 (May): 13330. doi: 10.1038/ncomms 13330.
    • 4. Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science (80-). 2016. doi: 10.1126/science.aaf8729.
    • 5. Hess G T, Tycko J, Yao D, Bassik M C. Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes. Mol Cell. 2017; 68:26-43. doi:10.1016/j.molcel.2017.09.029.
    • 6. Kim D, Lim K, Kim S-T, et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. 2017; 35(5):475-480. doi: 10.1038/nbt.3852.
    • 7. Rees H A, Komor A C, Yeh W-H, et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun. 2017. doi:10.1038/ncomms 15790.
    • 8. Kim, Daesik, Kayeong Lim, Sang-Tae Kim, Sun-Heui Yoon, Kyoungmi Kim, Seuk-Min Ryu, and Jin-Soo Kim. “Genome-wide Target Specificities of CRISPR RNA-guided Programmable Deaminases.” Nature Biotechnology (2017).
    • 9. Kleinstiver, Benjamin P., Vikram Pattanayak, Michelle S. Prew, Shengdar Q. Tsai, Nhu T. Nguyen, Zongli Zheng, and J. Keith Joung. “High-fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-wide Off-target Effects.” Nature 529.7587 (2016): 490-95.
    • 10. Slaymaker, I. M., L. Gao, B. Zetsche, D. A. Scott, W. X. Yan, and F. Zhang. “Rationally Engineered Cas9 Nucleases with Improved Specificity.” Science 351.6268 (2015): 84-88.
    • 11. Dahlman, James E., Omar O. Abudayyeh, Julia Joung, Jonathan S. Gootenberg, Feng Zhang, and Silvana Konermann. “Orthogonal Gene Knockout and Activation with a Catalytically Active Cas9 Nuclease.” Nature Biotechnology 33.11 (2015): 1159-161.
    • 12. Fu, Yanfang, et al. “Improving CRISPR-Cas nuclease specificity using truncated guide RNAs.” Nature biotechnology 32.3 (2014): 279-284.
    • 13. Boissel, S., J. Jarjour, A. Astrakhan, A. Adey, A. Gouble, P. Duchateau, J. Shendure, B. L. Stoddard, M. T. Certo, D. Baker, and A. M. Scharenberg. “MegaTALs: A Rare-cleaving Nuclease Architecture for Therapeutic Genome Engineering.” Nucleic Acids Research 42.4 (2013): 2591-601.
    • 14. Bolukbasi, Mehmet Fatih, Ankit Gupta, Sarah Oikemus, Alan G. Derr, Manuel Garber, Michael H. Brodsky, Lihua Julie Zhu, and Scot A. Wolfe. “DNA-binding-domain Fusions Enhance the Targeting Range and Precision of Cas9.” Nature Methods 12.12 (2015): 1150-156.
    • 15. Kleinstiver, Benjamin P., et al. “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition.” Nature biotechnology (2015).
    • 16. Ma, Enbo, et al. “Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes.” Molecular cell 60.3 (2015): 398-407.
    • 17. Komor A C, Zhao K T, Packer M S, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C: G-to-T: A base editors with higher efficiency and product purity. Sci Adv. 2017; (August): 1-10.
    • 18. CA2915837A1
    • 19. Friedland, Ari E., et al. “Characterization of Staphylococcus Aureus Cas9: a Smaller Cas9 for All-in-One Adeno-Associated Virus Delivery and Paired Nickase Applications.” Genome Biology, vol. 16, no. 1, 2015, doi:10.1186/s13059-015-0817-8.
    • 20. Gasiunas, G., et al. “Cas9-CrRNA Ribonucleoprotein Complex Mediates Specific DNA Cleavage for Adaptive Immunity in Bacteria.” Proceedings of the National Academy of Sciences, vol. 109, no. 39, April 2012, doi: 10.1073/pnas. 1208507109.
    • 21. Yamada, Mari, et al. “Crystal Structure of the Minimal Cas9 from Campylobacter Jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems.” Molecular Cell, vol. 65, no. 6, 2017, doi:10.1016j.molcel.2017.02.007.
    • 22. Zetsche, Bernd, et al. “Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System.” Cell, vol. 163, no. 3, 2015, pp. 759-771., doi:10.1016/j.cell.2015.09.038.
    • 23. Hirano, H., et al. “Crystal Structure of Francisella Novicida Cas9 RHA in Complex with GRNA and Target DNA (TGG PAM).” February 2016, doi: 10.2210/pdb5b2q/pdb.
    • 24. Yamano, T., et al. “Crystal Structure of Acidaminococcus Sp. Cpf1 in Complex with CrRNA and Target DNA.” April 2016, doi: 10.2210/pd
    • 25. Tang, Xu, et al. “A CRISPR-Cpf1 System for Efficient Genome Editing and Transcriptional Repression in Plants.” Nature Plants, vol. 3, no. 7, 2017, p. 17103, doi: 10.1038/nplants.2017.103.
    Other Embodiments
  • It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (40)

What is claimed is:
1. A fusion protein useful in a bipartite cytosine base editor system comprising:
(i) a first fusion protein comprising a non-R-loop-forming programmable DNA binding domain, preferably a transcription-activator-like effector (TALE) or zinc finger array (ZF), fused to a deaminase enzyme, or an active portion thereof, optionally with a linker therebetween, or
(ii) a second fusion protein comprising an R-loop-forming Cas9 protein that lacks nuclease activity or is a nickase, but can interact with a guide RNA and target DNA, fused to a Uracil glycosylase inhibitor (UGI), optionally with a linker therebetween.
2. The fusion protein of claim 1, wherein the first fusion protein comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
3. The fusion protein of claim 1, wherein the second fusion protein comprises an SpCas9 nickase or inactive nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or an inactive Cpf1 (dCpf1) protein.
4. The fusion protein of claim 3, wherein the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
5. The fusion protein of claim 1, wherein the DNA binding domain comprises a zinc finger DNA binding array.
6. A composition comprising a purified fusion protein of claims 1-5.
7. The composition of claim 6, further comprising a guide RNA that interacts with the Cas9 portion of the fusion protein.
8. The composition of claim 6, comprising one or more ribonucleoprotein (RNP) complexes.
9. A nucleic acid encoding the fusion protein of claims 1-5.
10. A vector comprising the nucleic acid of claim 9.
11. An isolated host cell expressing the fusion protein of claims 1-5.
12. A composition comprising a nucleic acid encoding the fusion protein of claims 1-5.
13. A method of targeted deamination of one or more selected cytosines in a nucleic acid, the method comprising contacting the nucleic acid with the fusion proteins of claims 1-5, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosines.
14. The method of claim 13, wherein the nucleic acid is in a cell, preferably a eukaryotic cell.
15. A method of targeted deamination of a nucleic acid in a cell, the method comprising expressing in the cell, or contacting the cell with, the fusion proteins of claims 1-5, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosine.
16. The method of claim 15, wherein the fusion protein is delivered as an RNP, mRNA, or plasmid.
17. A monomeric fusion protein comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, and optionally (iv) a fourth portion comprising a Uracil DNA glycosylase inhibitor (UGI), optionally with peptide linkers in between some or all of the first, second, third, or fourth portions, and wherein the domains (i)-(iv) can be in any order.
18. A fusion protein comprising (i) a first portion comprising a deaminase enzyme, or an active portion thereof, (ii) a second portion comprising a Cas9 protein that lacks nuclease activity or is a nickase and can interact with a guide RNA but does not sufficiently bind target DNA or form R-loops to potentiate genome editing or base events, such as type-II-C Cas9 orthologs or similarly deficient species, and (iii) a third portion comprising a DNA binding domain selected from zinc fingers and TALEs, optionally with peptide linkers in between some or all of the first, second, or third portions, and wherein the domains (i)-(iii) can be in any order.
19. The fusion proteins of claim 17 and 18, wherein the first portion comprises a cytidine deaminase selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1 (APOBEC1), APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G APOBEC3H, APOBEC4; activation induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1), and CDA2, and cytosine deaminase acting on tRNA (CDAT).
20. The fusion proteins of claim 17 or 18, wherein the second portion comprises an SpCas9 nuclease with a mutation at D10, E762, D839, H983, or D986 and H840 or N863, or a type-II-C Cas9 ortholog.
21. The fusion proteins of claim 20, wherein the mutation is one or both of D10A or D10N, or H840A/H840N/H840Y.
22. The fusion protein of claim 17 or 18, wherein the second portion comprises PlCas9, ClCas9, or NcCas9; or SpCas9, SaCas9, or CjCas9 with a mutations to a PAM interacting domain (PID).
23. The fusion proteins of claim 22, wherein the mutation to the PID is shown in Table 2.
24. The fusion proteins of claims 17 or 18, wherein the DNA binding domain comprises a zinc finger DNA binding array.
25. A composition comprising a purified fusion protein of claims 17-24.
26. A composition comprising the purified fusion protein of claim 18, and a protein comprising a Uracil DNA glycosylase inhibitor (UGI),
27. The composition of claims 25 or 26, further comprising a guide RNA that interacts with the Cas9 portion of the fusion protein.
28. The composition of claim 27, comprising one or more ribonucleoprotein (RNP) complexes.
29. A nucleic acid encoding the fusion protein of claims 17-24.
30. A vector comprising the nucleic acid of claim 29.
31. An isolated host cell expressing the fusion protein of claims 17-24.
32. A composition comprising a nucleic acid encoding the fusion protein of claims 17 or 19-24.
33. A method of targeted deamination of a selected cytosine in a nucleic acid, the method comprising contacting the nucleic acid with the fusion proteins of claims 17 or 19-24, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosine.
34. The method of claim 33, wherein the nucleic acid is in a cell.
35. A method of targeted deamination of a nucleic acid in a cell, the method comprising expressing in the cell, or contacting the cell with, the fusion proteins of claims 17 or 19-24, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosine.
36. The method of claim 35, wherein the fusion protein is delivered as an RNP, or as an mRNA or plasmid encoding the fusion protein.
37. A method of targeted deamination of a selected cytosine in a nucleic acid, the method comprising contacting the nucleic acid with the fusion protein of claim 18, a UGI protein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosine.
38. The method of claim 37, wherein the nucleic acid is in a cell.
39. A method of targeted deamination of a nucleic acid in a cell, the method comprising expressing in the cell, or contacting the cell with, the fusion protein of claim 18, a UGI protein, and a guide RNA (gRNA) that interacts with the Cas9 portion of the fusion protein and binds to a portion of the nucleic acid comprising or adjacent to the selected cytosine.
40. The method of claim 39, wherein the fusion protein is delivered as an RNP, or as an mRNA or plasmid encoding the fusion protein.
US16/616,014 2017-05-25 2018-05-25 Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing Pending US20200140842A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/616,014 US20200140842A1 (en) 2017-05-25 2018-05-25 Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511296P 2017-05-25 2017-05-25
US201762541544P 2017-08-04 2017-08-04
US201862622676P 2018-01-26 2018-01-26
US16/616,014 US20200140842A1 (en) 2017-05-25 2018-05-25 Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
PCT/US2018/034742 WO2018218206A1 (en) 2017-05-25 2018-05-25 Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing

Publications (1)

Publication Number Publication Date
US20200140842A1 true US20200140842A1 (en) 2020-05-07

Family

ID=64397083

Family Applications (4)

Application Number Title Priority Date Filing Date
US16/616,014 Pending US20200140842A1 (en) 2017-05-25 2018-05-25 Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
US16/615,559 Active US11326157B2 (en) 2017-05-25 2018-05-25 Base editors with improved precision and specificity
US16/615,538 Pending US20200172895A1 (en) 2017-05-25 2018-05-25 Using split deaminases to limit unwanted off-target base editor deamination
US17/739,418 Pending US20220275356A1 (en) 2017-05-25 2022-05-09 Base editors with improved precision and specificity

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/615,559 Active US11326157B2 (en) 2017-05-25 2018-05-25 Base editors with improved precision and specificity
US16/615,538 Pending US20200172895A1 (en) 2017-05-25 2018-05-25 Using split deaminases to limit unwanted off-target base editor deamination
US17/739,418 Pending US20220275356A1 (en) 2017-05-25 2022-05-09 Base editors with improved precision and specificity

Country Status (7)

Country Link
US (4) US20200140842A1 (en)
EP (3) EP3630849A4 (en)
JP (5) JP7324713B2 (en)
CN (3) CN110997728A (en)
AU (3) AU2018273986A1 (en)
CA (3) CA3063449A1 (en)
WO (3) WO2018218166A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113774085A (en) * 2021-08-20 2021-12-10 中国科学院广州生物医药与健康研究院 Single-base editing tool TaC9-ABE and application thereof
US11326157B2 (en) 2017-05-25 2022-05-10 The General Hospital Corporation Base editors with improved precision and specificity
CN115427564A (en) * 2020-03-04 2022-12-02 苏州齐禾生科生物科技有限公司 Improved cytosine base editing system
WO2023279118A3 (en) * 2021-07-02 2023-02-23 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
US11834686B2 (en) * 2018-08-23 2023-12-05 Sangamo Therapeutics, Inc. Engineered target specific base editors
CN117659210A (en) * 2023-11-30 2024-03-08 华南农业大学 Recombinant fusion protein used as plant double-base editor and application thereof
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2017044843A1 (en) 2015-09-11 2017-03-16 The General Hospital Corporation Full interrogation of nuclease dsbs and sequencing (find-seq)
EP4269577A3 (en) 2015-10-23 2024-01-17 President and Fellows of Harvard College Nucleobase editors and uses thereof
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN110214180A (en) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 The AAV of nucleobase editing machine is delivered
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
CN110914426A (en) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
BR112020003596A2 (en) 2017-08-23 2020-09-01 The General Hospital Corporation engineered crispr-cas9 nucleases with altered pam specificity
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3694993A4 (en) 2017-10-11 2021-10-13 The General Hospital Corporation Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
JP2021500036A (en) 2017-10-16 2021-01-07 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. Use of adenosine base editing factors
WO2019161783A1 (en) * 2018-02-23 2019-08-29 Shanghaitech University Fusion proteins for base editing
US11898203B2 (en) 2018-04-17 2024-02-13 The General Hospital Corporation Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents
JP2022521460A (en) * 2019-01-31 2022-04-08 ビーム セラピューティクス インク． Nucleobase editor with reduced off-target deamination and its use for modifying nucleobase target sequences
BR112021015092A2 (en) * 2019-02-02 2022-10-11 Univ Shanghai Technology FUSION PROTEIN, DUAL GUIDE RNA SYSTEM, E, GUIDE RNA
CN110804628B (en) * 2019-02-28 2023-05-12 中国科学院脑科学与智能技术卓越创新中心 High-specificity off-target-free single-base gene editing tool
BR112021018607A2 (en) 2019-03-19 2021-11-23 Massachusetts Inst Technology Methods and compositions for editing nucleotide sequences
CN112048497B (en) * 2019-06-06 2023-11-03 辉大(上海)生物科技有限公司 Novel single-base editing technology and application thereof
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
EP4031190A4 (en) * 2019-09-17 2023-08-09 Rutgers, the State University of New Jersey Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof
CN110564752B (en) * 2019-09-30 2021-07-16 北京市农林科学院 Application of differential agent technology in enrichment of C.T base substitution cells
CN112725348B (en) * 2019-10-28 2022-04-01 安徽省农业科学院水稻研究所 Gene and method for improving single-base editing efficiency of rice and application of gene
WO2021113611A1 (en) * 2019-12-06 2021-06-10 The General Hospital Corporation Split deaminase base editors
EP4093879A4 (en) * 2020-01-25 2024-02-28 Univ Pennsylvania Compositions for small molecule control of precise base editing of target nucleic acids and methods of use thereof
EP4097233A4 (en) * 2020-01-31 2024-02-28 Univ Massachusetts A cas9-pdbd base editor platform with improved targeting range and specificity
AU2021218811A1 (en) * 2020-02-13 2022-09-01 Beam Therapeutics Inc. Compositions and methods for engraftment of base edited cells
US20230116627A1 (en) * 2020-02-14 2023-04-13 Ohio State Innovation Foundation Nucleobase editors and methods of use thereof
CN116096873A (en) 2020-05-08 2023-05-09 布罗德研究所股份有限公司 Methods and compositions for editing two strands of a target double-stranded nucleotide sequence simultaneously
GB202010348D0 (en) 2020-07-06 2020-08-19 Univ Wageningen Base editing tools
KR20230061474A (en) * 2020-09-04 2023-05-08 고쿠리츠다이가쿠호진 고베다이가쿠 Double-stranded DNA modification complex containing miniaturized cytidine deaminase
JPWO2022050377A1 (en) 2020-09-04 2022-03-10
AU2021350099A1 (en) * 2020-09-25 2023-04-27 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
KR102399035B1 (en) * 2020-10-21 2022-05-17 성균관대학교산학협력단 Vector expressing cytosine base editor without off-target effect without reduction of on-target efficiency in industrial strains and uses thereof
US20220372497A1 (en) * 2021-05-18 2022-11-24 Shanghaitech University Base Editing Tool And Use Thereof
WO2023050169A1 (en) * 2021-09-29 2023-04-06 深圳先进技术研究院 Method for achieving tag-to-taa conversion on genome with high throughput
WO2023122722A1 (en) * 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
CN114774399B (en) * 2022-03-25 2024-01-30 武汉大学 Method for artificially modifying single-base resolution positioning analysis of 5-hydroxymethylcytosine modification in deaminase-assisted DNA
CN114686456B (en) * 2022-05-10 2023-02-17 中山大学 Base editing system based on bimolecular deaminase complementation and application thereof
WO2023217280A1 (en) * 2022-05-13 2023-11-16 Huidagene Therapeutics Co., Ltd. Programmable adenine base editor and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407205T1 (en) 1994-08-20 2008-09-15 Gendaq Ltd IMPROVEMENT IN BINDING PROTEINS IN DNA DETECTION
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
CA2394850C (en) 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
AU2001257331A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
AU2003304086A1 (en) 2002-10-23 2004-11-26 Massachussetts Institute Of Technlogy Context sensitive parallel optimization of zinc finger dna binding domains
AU2006282983B2 (en) 2005-08-26 2012-08-02 Dupont Nutrition Biosciences Aps Use
US20100100976A1 (en) 2006-08-28 2010-04-22 University Of Rochester Methods and compositions related to apobec-1 expression
NZ579002A (en) 2007-03-02 2012-03-30 Danisco Cultures with improved phage resistance
FR2925918A1 (en) 2007-12-28 2009-07-03 Pasteur Institut Typing or subtyping Salmonella bacteria comprises determining the variable sequence composition of a nucleic acid fragment amplified from the CRISPR1 and/or CRISPR2 locus
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
MX337838B (en) 2008-11-07 2016-03-22 Dupont Nutrition Biosci Aps Bifidobacteria crispr sequences.
DK2367938T3 (en) 2008-12-12 2014-08-25 Dupont Nutrition Biosci Aps GENETIC CLUSTER OF TREASURES OF STREPTOCOCCUS THERMOPHILUS WITH UNIQUE RHEOLOGICAL PROPERTIES FOR MILK Fermentation
WO2010132092A2 (en) * 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
CA2798703A1 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
EA201390586A1 (en) 2010-10-20 2014-11-28 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС CRISPR-CAS LACTOCOCCUS SEQUENCES
US20140201857A1 (en) 2013-01-14 2014-07-17 Recombinetics, Inc. Hornless livestock
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
BR112014020625A2 (en) 2012-02-24 2017-07-04 Hutchinson Fred Cancer Res polynucleotide, polypeptide, composition, cell, and stem cell edited by genome
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
MX362866B (en) 2012-05-25 2019-02-20 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription.
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
US9258704B2 (en) 2012-06-27 2016-02-09 Advanced Messaging Technologies, Inc. Facilitating network login
WO2014071235A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
PT3138910T (en) 2012-12-06 2017-10-18 Sigma Aldrich Co Llc Crispr-based genome modification and regulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP2932421A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CN113528577A (en) 2012-12-12 2021-10-22 布罗德研究所有限公司 Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2931897B1 (en) 2012-12-12 2017-11-01 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
JP6473419B2 (en) 2012-12-13 2019-02-20 ダウ アグロサイエンシィズ エルエルシー DNA detection method for site-specific nuclease activity
KR20150095861A (en) 2012-12-17 2015-08-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-guided human genome engineering
US20140212869A1 (en) 2013-01-25 2014-07-31 Agilent Technologies, Inc. Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
JP2016519652A (en) 2013-03-14 2016-07-07 カリブー・バイオサイエンシーズ・インコーポレイテッド Nucleic acid targeting nucleic acid compositions and methods
US20140273235A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP3988667A1 (en) 2013-03-15 2022-04-27 The General Hospital Corporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CA2908512C (en) 2013-04-05 2023-10-24 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US20150056629A1 (en) 2013-04-14 2015-02-26 Katriona Guthrie-Honea Compositions, systems, and methods for detecting a DNA sequence
SG11201508028QA (en) 2013-04-16 2015-10-29 Regeneron Pharma Targeted modification of rat genome
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US20150067922A1 (en) 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
EP3022304B1 (en) 2013-07-19 2018-12-26 Larix Biosciences LLC Methods and compositions for producing double allele knock outs
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
EA037850B1 (en) 2013-08-29 2021-05-27 Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Methods and compositions for rna-guided treatment of hiv infection
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) * 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
CN105980568B (en) 2013-12-11 2019-12-03 瑞泽恩制药公司 Method and composition for targeting modification genome
BR112016013213A2 (en) 2013-12-12 2017-12-05 Massachusetts Inst Technology administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
CA2935032C (en) 2013-12-26 2024-01-23 The General Hospital Corporation Multiplex guide rnas
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
DK3180426T3 (en) 2014-08-17 2020-03-30 Broad Inst Inc RETURNING BY USING CAS9 NICKASES
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
EP3237017A4 (en) * 2014-12-24 2018-08-01 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
US20180155708A1 (en) * 2015-01-08 2018-06-07 President And Fellows Of Harvard College Split Cas9 Proteins
CN107532161A (en) 2015-03-03 2018-01-02 通用医疗公司 The specific engineering CRISPR Cas9 nucleases of PAM with change
US20180291372A1 (en) * 2015-05-14 2018-10-11 Massachusetts Institute Of Technology Self-targeting genome editing system
JP7044373B2 (en) * 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー Nuclease-independent targeted gene editing platform and its uses
EP3341477B1 (en) 2015-08-28 2022-03-23 The General Hospital Corporation Engineered crispr-cas9 nucleases
US9926546B2 (en) * 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP4269577A3 (en) * 2015-10-23 2024-01-17 President and Fellows of Harvard College Nucleobase editors and uses thereof
WO2017173092A1 (en) * 2016-03-31 2017-10-05 The Regents Of The University Of California Methods for genome editing in zygotes
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
CN110914426A (en) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 Nucleobase editors comprising nucleic acid programmable DNA binding proteins
CA3059956A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
US20200140842A1 (en) 2017-05-25 2020-05-07 The General Hospital Corporation Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
BR112020003596A2 (en) 2017-08-23 2020-09-01 The General Hospital Corporation engineered crispr-cas9 nucleases with altered pam specificity
US20210395730A1 (en) 2018-10-10 2021-12-23 The General Hospital Corporation Selective Curbing of Unwanted RNA Editing (SECURE) DNA Base Editor Variants
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
WO2021042062A2 (en) 2019-08-30 2021-03-04 Joung J Keith Combinatorial adenine and cytosine dna base editors
EP4022053A4 (en) 2019-08-30 2023-05-31 The General Hospital Corporation C-to-g transversion dna base editors
WO2021113611A1 (en) 2019-12-06 2021-06-10 The General Hospital Corporation Split deaminase base editors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ma et al., "Integration and exchange of split dCas9 domains for transcriptional controls in mammalian cells", Nat. Comm. 7:13056, 2016, 7 pages (Year: 2016) *
Mali et al., Nat. Biotechnol. 31:833-, 2013 (Year: 2013) *
Singh et al., Curr. Protein Pept. Sci. 18:1-11, 2017 (Year: 2017) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11326157B2 (en) 2017-05-25 2022-05-10 The General Hospital Corporation Base editors with improved precision and specificity
US11834686B2 (en) * 2018-08-23 2023-12-05 Sangamo Therapeutics, Inc. Engineered target specific base editors
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
CN115427564A (en) * 2020-03-04 2022-12-02 苏州齐禾生科生物科技有限公司 Improved cytosine base editing system
WO2023279118A3 (en) * 2021-07-02 2023-02-23 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
CN113774085A (en) * 2021-08-20 2021-12-10 中国科学院广州生物医药与健康研究院 Single-base editing tool TaC9-ABE and application thereof
CN117659210A (en) * 2023-11-30 2024-03-08 华南农业大学 Recombinant fusion protein used as plant double-base editor and application thereof

Also Published As

Publication number Publication date
WO2018218188A2 (en) 2018-11-29
US20220275356A1 (en) 2022-09-01
CA3063449A1 (en) 2018-11-29
JP2020521451A (en) 2020-07-27
EP3630198A1 (en) 2020-04-08
EP3630849A1 (en) 2020-04-08
JP2023126956A (en) 2023-09-12
EP3630970A2 (en) 2020-04-08
EP3630198A4 (en) 2021-04-21
AU2018273968A1 (en) 2019-11-28
JP2020521454A (en) 2020-07-27
JP2020521446A (en) 2020-07-27
US20200172895A1 (en) 2020-06-04
JP2023113672A (en) 2023-08-16
CA3063733A1 (en) 2018-11-29
AU2018272067A1 (en) 2019-11-28
WO2018218166A1 (en) 2018-11-29
CN110997728A (en) 2020-04-10
EP3630970A4 (en) 2020-12-30
CN111093714A (en) 2020-05-01
WO2018218206A1 (en) 2018-11-29
EP3630849A4 (en) 2021-01-13
WO2018218188A3 (en) 2019-01-03
CN110959040A (en) 2020-04-03
JP7324713B2 (en) 2023-08-10
US11326157B2 (en) 2022-05-10
US20200172885A1 (en) 2020-06-04
AU2018273986A1 (en) 2019-12-12
CA3064828A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
US20200140842A1 (en) Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
US11946040B2 (en) Adenine DNA base editor variants with reduced off-target RNA editing
US20220017883A1 (en) Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
AU2017341926B2 (en) Epigenetically regulated site-specific nucleases
WO2021042062A2 (en) Combinatorial adenine and cytosine dna base editors
WO2021042047A1 (en) C-to-g transversion dna base editors
WO2020077138A2 (en) Selective curbing of unwanted rna editing (secure) dna base editor variants
US20230024833A1 (en) Split deaminase base editors
WO2021108501A1 (en) System and method for activating gene expression
WO2024086845A2 (en) Engineered casphi2 nucleases
BASE Adenine Dna Base Editor Variants With Reduced Off-target Rna Editing

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOUNG, J. KEITH;ANGSTMAN, JAMES;GEHRKE, JASON MICHAEL;AND OTHERS;SIGNING DATES FROM 20201103 TO 20210525;REEL/FRAME:056817/0433

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED